{
  "letters": 425152,
  "pages": 118,
  "meta": {
    "end_of_period": {
      "year": 2022,
      "month": 12
    },
    "company_name": "Syndax Pharmaceuticals, Inc.",
    "major_industry": "Healthcare",
    "mentions_recent_mergers_and_acquisitions": {
      "value": true,
      "elements": [
        {
          "type": "merger_acquisition",
          "page": 1,
          "title": "Securities Registration",
          "data": [
            {
              "key": "Title of each class",
              "value": "Common Stock"
            },
            {
              "key": "Trading Symbol(s)",
              "value": "SNDX"
            },
            {
              "key": "Name of each exchange on which registered",
              "value": "The Nasdaq Stock Market, LLC"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 16,
          "title": "Entinostat Patent Portfolio",
          "data": [
            {
              "key": "Patent Applications",
              "value": "four owned pending U.S. non-provisional patent applications, three owned granted U.S. patents"
            },
            {
              "key": "U.S. Patents",
              "value": "U.S. Patent Nos. 10,226,472, 11,324,822, 11,397,184"
            },
            {
              "key": "Expiration Dates",
              "value": "August 2032, March 2036 and September 2036"
            },
            {
              "key": "Non-U.S. Patents",
              "value": "nine granted non-U.S. patents, three allowed non-U.S. patent applications, and 39 owned non-U.S. pending patent applications"
            },
            {
              "key": "Licensor",
              "value": "Bayer"
            },
            {
              "key": "Bayer Portfolio Summary",
              "value": "seven issued U.S. patents, 62 granted non-U.S. patents, 17 patent applications pending in non-U.S. patent offices"
            },
            {
              "key": "Specific Patents of Interest",
              "value": "reissue U.S. Patent RE39,754, U.S. Patent 7,973,166"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 79,
          "title": "Exhibit No. 10.33",
          "data": [
            {
              "key": "Description",
              "value": "Amendment No. 1 to License Agreement by and between the Company and UCB Biopharma Sprl, dated as of July 9, 2019."
            },
            {
              "key": "Reference",
              "value": "Incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q (File No. 001-37708), as filed with the SEC on November 7, 2019."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 79,
          "title": "Exhibit No. 10.34",
          "data": [
            {
              "key": "Description",
              "value": "License Agreement by and between the Company and Vitae Pharmaceuticals, Inc., dated as of October 13, 2017."
            },
            {
              "key": "Reference",
              "value": "Incorporated by reference to Exhibit 10.47 to the Company’s Annual Report on Form 10-K (File No. 001-37708), as filed with the SEC on March 8, 2018."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 79,
          "title": "Exhibit No. 10.35",
          "data": [
            {
              "key": "Description",
              "value": "Amendment No. 1 to License Agreement by and between the Company and Vitae Pharmaceuticals, Inc., dated as of January 25, 2019."
            },
            {
              "key": "Reference",
              "value": "Incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q (File No. 001-37708), as filed with the SEC on May 8, 2019."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 79,
          "title": "Exhibit No. 10.36",
          "data": [
            {
              "key": "Description",
              "value": "Collaboration and License Agreement by and between the Company and Incyte Corporation, dated as of September 24, 2021."
            },
            {
              "key": "Reference",
              "value": "Incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q (File No. 001-37708), as filed with the SEC on November 15, 2021."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 79,
          "title": "Exhibit No. 10.37",
          "data": [
            {
              "key": "Description",
              "value": "Purchase Agreement by and between the Company and Incyte Corporation, dated as of September 24, 2021."
            },
            {
              "key": "Reference",
              "value": "Incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q (File No. 001-37708), as filed with the SEC on November 15, 2021."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 102,
          "title": "Fair Value Measurements and Unobservable Inputs",
          "data": [
            {
              "key": "Liabilities:",
              "value": ""
            },
            {
              "key": "Derivative Liability",
              "value": ""
            },
            {
              "key": "Fair Value",
              "value": "187"
            },
            {
              "key": "Unobservable Input",
              "value": "Discount Rate"
            },
            {
              "key": "Range",
              "value": "4-5%"
            },
            {
              "key": "Weighted Average",
              "value": "4.5%"
            },
            {
              "key": "Volatility",
              "value": ""
            },
            {
              "key": "Range",
              "value": "58-61%"
            },
            {
              "key": "Weighted Average",
              "value": "59.5%"
            },
            {
              "key": "Expected Timing of the Termination Right",
              "value": ""
            },
            {
              "key": "Range",
              "value": "9 months"
            },
            {
              "key": "Weighted Average",
              "value": "9 months"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 102,
          "title": "Derivative Liability",
          "data": [
            {
              "key": "Beginning Balance 1/1",
              "value": "187"
            },
            {
              "key": "Additions",
              "value": ""
            },
            {
              "key": "Change in Fair Value",
              "value": "-187"
            },
            {
              "key": "Ending Balance 12/31",
              "value": "0"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 102,
          "title": "Investment Securities Summary - December 31, 2022 and 2021",
          "data": [
            {
              "key": "Security Type",
              "value": "Commercial paper"
            },
            {
              "key": "Amortized Cost",
              "value": "321630"
            },
            {
              "key": "Unrealized Gains",
              "value": "0"
            },
            {
              "key": "Unrealized Losses",
              "value": "-205"
            },
            {
              "key": "Fair Value",
              "value": "321425"
            },
            {
              "key": "Year",
              "value": "2022"
            },
            {
              "key": "Security Type",
              "value": "US Treasury"
            },
            {
              "key": "Amortized Cost",
              "value": "64759"
            },
            {
              "key": "Unrealized Gains",
              "value": "0"
            },
            {
              "key": "Unrealized Losses",
              "value": "-566"
            },
            {
              "key": "Fair Value",
              "value": "64193"
            },
            {
              "key": "Year",
              "value": "2022"
            },
            {
              "key": "Security Type",
              "value": "Federal bonds"
            },
            {
              "key": "Amortized Cost",
              "value": "36192"
            },
            {
              "key": "Unrealized Gains",
              "value": "0"
            },
            {
              "key": "Unrealized Losses",
              "value": "-35"
            },
            {
              "key": "Fair Value",
              "value": "36157"
            },
            {
              "key": "Year",
              "value": "2022"
            },
            {
              "key": "Security Type",
              "value": "2022 Total"
            },
            {
              "key": "Amortized Cost",
              "value": "422581"
            },
            {
              "key": "Unrealized Gains",
              "value": "0"
            },
            {
              "key": "Unrealized Losses",
              "value": "-806"
            },
            {
              "key": "Fair Value",
              "value": "421775"
            },
            {
              "key": "Year",
              "value": "2022"
            },
            {
              "key": "Security Type",
              "value": "Commercial paper"
            },
            {
              "key": "Amortized Cost",
              "value": "306715"
            },
            {
              "key": "Unrealized Gains",
              "value": "70"
            },
            {
              "key": "Unrealized Losses",
              "value": "-17"
            },
            {
              "key": "Fair Value",
              "value": "306768"
            },
            {
              "key": "Year",
              "value": "2021"
            },
            {
              "key": "Security Type",
              "value": "Corporate bonds"
            },
            {
              "key": "Amortized Cost",
              "value": "22147"
            },
            {
              "key": "Unrealized Gains",
              "value": "0"
            },
            {
              "key": "Unrealized Losses",
              "value": "-6"
            },
            {
              "key": "Fair Value",
              "value": "22141"
            },
            {
              "key": "Year",
              "value": "2021"
            },
            {
              "key": "Security Type",
              "value": "US Treasury"
            },
            {
              "key": "Amortized Cost",
              "value": "14212"
            },
            {
              "key": "Unrealized Gains",
              "value": "0"
            },
            {
              "key": "Unrealized Losses",
              "value": "-2"
            },
            {
              "key": "Fair Value",
              "value": "14210"
            },
            {
              "key": "Year",
              "value": "2021"
            },
            {
              "key": "Security Type",
              "value": "2021 Total"
            },
            {
              "key": "Amortized Cost",
              "value": "343074"
            },
            {
              "key": "Unrealized Gains",
              "value": "70"
            },
            {
              "key": "Unrealized Losses",
              "value": "-25"
            },
            {
              "key": "Fair Value",
              "value": "343119"
            },
            {
              "key": "Year",
              "value": "2021"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_leadership_changes": {
      "value": true,
      "elements": [
        {
          "type": "leadership_change",
          "page": 75,
          "title": "Directors, Executive Officers, and Corporate Governance",
          "data": [
            {
              "key": "incorporation",
              "value": "Information required is incorporated by reference from 2023 Proxy Statement"
            },
            {
              "key": "focus_sections",
              "value": "Information About Our Board of Directors, Executive Officers, and The Board of Directors and Its Committees"
            },
            {
              "key": "Code of Conduct",
              "value": "Information regarding Code of Business Conduct and Ethics will be contained in 2023 Proxy Statement"
            },
            {
              "key": "amendments_disclosures",
              "value": "Any substantive amendments or waivers will be disclosed on their website"
            },
            {
              "key": "website",
              "value": "www.syndax.com"
            },
            {
              "key": "additional_items",
              "value": "Executive Compensation, Security Ownership, Certain Relationships and Related Transactions, Principal Accountant Fees and Services incorporated by reference from 2023 Proxy Statement"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 80,
          "title": "Corporate Officers and Directors Signatures",
          "data": [
            {
              "key": "CEO",
              "value": "Michael A. Metzger – Chief Executive Officer and Director; signed on February 28, 2023"
            },
            {
              "key": "CFO",
              "value": "Keith Goldan – Chief Financial Officer and Principal Financial Officer; signed on February 28, 2023"
            },
            {
              "key": "Chairman",
              "value": "Dennis G. Podlesak – Chairman of the Board of Directors; signed on February 28, 2023"
            },
            {
              "key": "Director",
              "value": "Martin H. Huber, M.D. – Director; signature appears with and without printed name, signed on February 28, 2023"
            },
            {
              "key": "Director",
              "value": "Jennifer Jarrett – Director; signed on February 28, 2023"
            },
            {
              "key": "Director",
              "value": "Keith A. Katkin – Director; signature line present (date not provided in one instance)"
            },
            {
              "key": "Director",
              "value": "Pierre Legault – Director; signed on February 28, 2023"
            },
            {
              "key": "Director",
              "value": "William Meury – Director; signed on February 28, 2023"
            },
            {
              "key": "President & Head of Research",
              "value": "Briggs W. Morrison, MD. – President, Head of Research (truncated title); signed on February 28, 2023"
            },
            {
              "key": "Power of Attorney",
              "value": "Each signatory authorizes Michael A. Metzger and Luke J. Albrecht, with full substitution powers, to act as attorney-in-fact to file amendments and related documents with the SEC."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 81,
          "title": "Briggs W. Morrison, MD. 77 Development, Director",
          "data": [
            {
              "key": "Name",
              "value": "Briggs W. Morrison, MD"
            },
            {
              "key": "Department",
              "value": "77 Development"
            },
            {
              "key": "Position",
              "value": "Director"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_layoffs": {
      "value": true,
      "elements": [
        {
          "type": "layoff",
          "page": 100,
          "title": "UCB License Agreement",
          "data": [
            {
              "key": "responsibility",
              "value": "The Company will be solely responsible for the development and commercialization of SNDX-6352."
            },
            {
              "key": "termination_conditions",
              "value": "Each party may terminate the UCB License Agreement for the other party’s uncured material breach or insolvency."
            },
            {
              "key": "milestone_expenses",
              "value": "The Company paid UCB $5.8 million as a milestone expense."
            },
            {
              "key": "expiration_terms",
              "value": "The UCB License Agreement will continue until the expiration of all licensed patent rights or 10 years from the date of the first commercial sale."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "layoff",
          "page": 100,
          "title": "Property and Equipment Summary",
          "data": [
            {
              "key": "total_property_and_equipment_2022",
              "value": "419"
            },
            {
              "key": "total_property_and_equipment_2021",
              "value": "721"
            },
            {
              "key": "net_property_and_equipment_2022",
              "value": "20"
            },
            {
              "key": "net_property_and_equipment_2021",
              "value": "278"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_executive_compensation": {
      "value": true,
      "elements": [
        {
          "type": "executive_compensation",
          "page": 7,
          "title": "Clinical Trial Updates for Revumenib",
          "data": [
            {
              "key": "Trial Name",
              "value": "AUGMENT-101"
            },
            {
              "key": "Design",
              "value": "Phase 1 dose escalation"
            },
            {
              "key": "Patient populations",
              "value": "R/R NPM1 mutant AML, R/R KMT2Ar AML, KMT2Ar ALL"
            },
            {
              "key": "Overall response rate",
              "value": "53% (32/60)"
            },
            {
              "key": "CR/CRh rate",
              "value": "30% (18/60)"
            },
            {
              "key": "MRD negativity rate",
              "value": "78% (14/18)"
            },
            {
              "key": "Median time to response",
              "value": "1.9 months"
            },
            {
              "key": "Median duration of response",
              "value": "9.1 months"
            },
            {
              "key": "Treatment related adverse events",
              "value": "Grade 3 QT prolongation, diarrhea (3%), fatigue (3%), anemia (3%)"
            },
            {
              "key": "Ongoing Trials",
              "value": "BEAT-AML, AUGMENT-102, INTERCEPT"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 11,
          "title": "Collaboration and License Agreement with Incyte",
          "data": [
            {
              "key": "Upfront Cash Payment",
              "value": "$117 million"
            },
            {
              "key": "Shares Issued",
              "value": "1,421,523 shares"
            },
            {
              "key": "Purchase Price per Share",
              "value": "$24.62"
            },
            {
              "key": "Potential Contingent Development and Regulatory Milestones",
              "value": "$220 million"
            },
            {
              "key": "Potential Commercialization Milestones",
              "value": "$230 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 14,
          "title": "Intellectual Property and Commercialization Strategy",
          "data": [
            {
              "key": "Development Agreement",
              "value": "Development of entinostat in the Eddingpharm territory will be made by us out of the payments we receive from Eddingpharm. The agreement with Eddingpharm will expire with respect to each country upon the expiration of all royalty payment obligations."
            },
            {
              "key": "Termination Clauses",
              "value": "May terminate the agreement upon written notice if Eddingpharm challenges validity of patents. Eddingpharm may terminate for convenience at any time."
            },
            {
              "key": "Sales and Marketing Strategy",
              "value": "Building commercial infrastructure to support sales of product candidates primarily focusing on medical oncologists."
            },
            {
              "key": "Manufacturing Strategy",
              "value": "Rely on third-party contract manufacturers and do not own manufacturing facilities."
            },
            {
              "key": "Patent Protection",
              "value": "Seek patent protection in the US and internationally for product candidates and methods of use."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 77,
          "title": "Exhibit Index",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "10.5*"
            },
            {
              "key": "Description",
              "value": "2007 Stock Plan Amendment, dated as of December 17, 2014 (incorporated herein by reference to Exhibit 10.7 to the Company's Registration Statement on Form S-1 (File No. 333-208861), as filed with the SEC on January 4, 2016)."
            },
            {
              "key": "Exhibit Number",
              "value": "10.6*"
            },
            {
              "key": "Description",
              "value": "2007 Stock Plan Amendment, dated as of May 28, 2015 (incorporated herein by reference to Exhibit 10.8 to the Company's Registration Statement on Form S-1 (File No. 333-208861), as filed with the SEC on January 4, 2016)."
            },
            {
              "key": "Exhibit Number",
              "value": "10.7*"
            },
            {
              "key": "Description",
              "value": "2007 Stock Plan Amendment, dated as of August 20, 2015 (incorporated herein by reference to Exhibit 10.9 to the Company's Registration Statement on Form S-1 (File No. 333-208861), as filed with the SEC on January 4, 2016)."
            },
            {
              "key": "Exhibit Number",
              "value": "10.8*"
            },
            {
              "key": "Description",
              "value": "Form of Incentive Stock Option Agreement under 2007 Stock Plan (incorporated herein by reference to Exhibit 10.10 to the Company's Registration Statement on Form S-1 (File No. 333-208861), as filed with the SEC on January 4, 2016)."
            },
            {
              "key": "Exhibit Number",
              "value": "10.9*"
            },
            {
              "key": "Description",
              "value": "Form of Non-Statutory Stock Option Agreement under 2007 Stock Plan (incorporated herein by reference to Exhibit 10.11 to the Company's Registration Statement on Form S-1 (File No. 333-208861), as filed with the SEC on January 4, 2016)."
            },
            {
              "key": "Exhibit Number",
              "value": "10.10*"
            },
            {
              "key": "Description",
              "value": "2015 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.12 to the Company's Registration Statement on Form S-8 (File No. 333-210412), as filed with the SEC on March 25, 2016)."
            },
            {
              "key": "Exhibit Number",
              "value": "10.11*"
            },
            {
              "key": "Description",
              "value": "Form of Incentive Stock Option Agreement under 2015 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.13 to the Company's Registration Statement on Form S-1 (File No. 333-208861), as filed with the SEC on January 4, 2016)."
            },
            {
              "key": "Exhibit Number",
              "value": "10.12*"
            },
            {
              "key": "Description",
              "value": "Form of Non-Qualified Option Agreement under 2015 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.14 to the Company's Registration Statement on Form S-1 (File No. 333-208861), as filed with the SEC on January 4, 2016)."
            },
            {
              "key": "Exhibit Number",
              "value": "10.13*"
            },
            {
              "key": "Description",
              "value": "Form of Stock Unit Agreement under 2015 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q (File No. 001-37708), as filed with the SEC on August 6, 2020)."
            },
            {
              "key": "Exhibit Number",
              "value": "10.14*"
            },
            {
              "key": "Description",
              "value": "Form of Deferred Settlement Stock Unit Agreement under 2015 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.14 to the Company's Annual Report on Form 10-K (file No. 001-37708), as filed with the SEC on March 12, 2021)."
            },
            {
              "key": "Exhibit Number",
              "value": "10.15*"
            },
            {
              "key": "Description",
              "value": "2015 Employee Stock Purchase Plan (incorporated herein by reference to Exhibit 4.16 to the Company's Registration Statement on Form S-8 (File No. 333-210412), as filed with the SEC on March 25, 2016)."
            },
            {
              "key": "Exhibit Number",
              "value": "10.16*"
            },
            {
              "key": "Description",
              "value": "Syndax Pharmaceuticals, Inc. 2023 Inducement Plan (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K (File No. 001-37708), as filed with the SEC on February 8, 2023)."
            },
            {
              "key": "Exhibit Number",
              "value": "10.17*"
            },
            {
              "key": "Description",
              "value": "Form of Option Agreement pursuant to the Syndax Pharmaceuticals, Inc. 2023 Inducement Plan (incorporated herein by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K (File No. 001-37708), as filed with the SEC on February 8, 2023)."
            },
            {
              "key": "Exhibit Number",
              "value": "10.18*"
            },
            {
              "key": "Description",
              "value": "Amended and Restated Executive Employment Agreement by and between the Company and Briggs W. Morrison, M.D., dated as of February 2, 2022 (incorporated herein by reference to Exhibit 10.16 to the Company's Annual Report on Form 10-K (File No. 001- 37708), as filed with the SEC on March 1, 2022)."
            },
            {
              "key": "Exhibit Number",
              "value": "10.19*"
            },
            {
              "key": "Description",
              "value": "Amended and Restated Executive Employment Agreement by and between the Company and Michael A. Metzger, dated as of February 2, 2022 (incorporated herein by reference to Exhibit 10.17 to the."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 78,
          "title": "Executive Employment Agreements",
          "data": [
            {
              "key": "Document 1",
              "value": "Executive Employment Agreement by and between the Company and Catherine Madigan, M.D., dated as of March 1, 2022."
            },
            {
              "key": "Document 2",
              "value": "Executive Employment Agreement by and between the Company and Anjali Ganguli, Ph.D., dated as of September 30, 2021."
            },
            {
              "key": "Document 3",
              "value": "Executive Employment Agreement by and between the Company and Keith A. Goldan, dated as of June 8, 2022."
            },
            {
              "key": "Document 4",
              "value": "Executive Employment Agreement by and between the Company and Steve M. Sabus, dated as of December 1, 2022."
            },
            {
              "key": "Document 5",
              "value": "Non-employee Director Compensation Policy, as amended, dated as of February 2, 2023."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 98,
          "title": "Operating Lease Payment Schedule",
          "data": [
            {
              "key": "2023",
              "value": "567"
            },
            {
              "key": "2024",
              "value": "585"
            },
            {
              "key": "Thereafter",
              "value": "199"
            },
            {
              "key": "Total lease payments",
              "value": "1351"
            },
            {
              "key": "Less: imputed interest",
              "value": "-208"
            },
            {
              "key": "Total operating lease liability",
              "value": "1143"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 98,
          "title": "Earnings Per Share Calculation Components",
          "data": [
            {
              "key": "Net (loss) income",
              "value": "-149338, 24926, -73158"
            },
            {
              "key": "Deemed dividend due to warrant reset",
              "value": "= = (3,906)"
            },
            {
              "key": "Net (loss) income attributable to common stockholders",
              "value": "-149338, 24926, -77064"
            },
            {
              "key": "Weighted-average common shares outstanding",
              "value": "60761, 52065, 41308"
            },
            {
              "key": "Options to purchase common stock",
              "value": "=, 1429, ="
            },
            {
              "key": "Non - vested restricted stock units (RSUs)",
              "value": "=, 118, ="
            },
            {
              "key": "ESPP to purchase common stock",
              "value": "null, null, null"
            },
            {
              "key": "Dilutive potential common shares",
              "value": "=, 1558, ="
            },
            {
              "key": "Shares used in calculating diluted earnings (loss) per share",
              "value": "60761, 53623, 41308"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 99,
          "title": "Stock-Based Compensation Distribution",
          "data": [
            {
              "key": "Options to purchase common",
              "value": "7,982"
            },
            {
              "key": "Non-vested restricted stock units (RSUs)",
              "value": "131"
            },
            {
              "key": "SPP to purchase common stock",
              "value": "17"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 104,
          "title": "Potential Share Issuances and Stock-Based Compensation",
          "data": [
            {
              "key": "Common stock issuable under pre-funded warrants",
              "value": "1,142,856"
            },
            {
              "key": "Options to purchase common stock",
              "value": "8,924,365"
            },
            {
              "key": "Employee Stock Purchase Plan",
              "value": "1,517,411"
            },
            {
              "key": "Total",
              "value": "11,584,632"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 105,
          "title": "Executive Compensation Overview",
          "data": [
            {
              "key": "Compensation Expense Recognition",
              "value": "Stock-based awards are subject to service or performance-based vesting conditions and recognized over the associated service period."
            },
            {
              "key": "2017 Performance Awards",
              "value": "Company granted 60,000 options, with 13,333 vesting in 2019. 20,000 were cancelled by January 1, 2021."
            },
            {
              "key": "Stock Compensation Recorded",
              "value": "$6,000 (2022), $25,000 (2021), and $9,000 (2020) associated with 2017 Performance Awards."
            },
            {
              "key": "2019 Performance Awards",
              "value": "Company granted 583,000 stock options related to clinical and regulatory development milestones."
            },
            {
              "key": "2022 Performance Awards",
              "value": "Company granted 140,000 options related to regulatory development milestones."
            },
            {
              "key": "Achievement of Performance Milestones",
              "value": "One milestone for 2019 Performance Awards achieved in Q4 2020, recorded compensation of $128,000 (2022) and $257,000 (2021)."
            },
            {
              "key": "Unvested Options",
              "value": "As of December 31, 2022, 140,000 stock options for 2022 Performance Awards were outstanding and unvested."
            },
            {
              "key": "Severance and Consulting Agreements",
              "value": "In October 2021, agreements extended vesting for 34,728 unvested options, recognizing $0.8 million in incremental stock compensation."
            },
            {
              "key": "Valuation Method",
              "value": "Grant date fair values estimated using Black-Scholes model."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 106,
          "title": "Financial Metrics Summary",
          "data": [
            {
              "key": "Volatility rate (2022)",
              "value": "77.87%"
            },
            {
              "key": "Volatility rate (2021)",
              "value": "85.84%"
            },
            {
              "key": "Volatility rate (2020)",
              "value": "81.59%"
            },
            {
              "key": "Risk-free interest rate (2022)",
              "value": "2.52%"
            },
            {
              "key": "Risk-free interest rate (2021)",
              "value": "0.67%"
            },
            {
              "key": "Risk-free interest rate (2020)",
              "value": "1.20%"
            },
            {
              "key": "Expected dividend yield (2022)",
              "value": "0.00 %"
            },
            {
              "key": "Expected dividend yield (2021)",
              "value": "0.00 %"
            },
            {
              "key": "Expected dividend yield (2020)",
              "value": "0.00 %"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 106,
          "title": "Stock Options Activity Summary 2022",
          "data": [
            {
              "key": "Outstanding—January 1, 2022",
              "value": "6921514 options"
            },
            {
              "key": "Granted",
              "value": "3020850 options"
            },
            {
              "key": "Exercised",
              "value": "-1276361 options"
            },
            {
              "key": "Cancelled, forfeited or expired",
              "value": "-684326 options"
            },
            {
              "key": "Outstanding—December 31, 2022",
              "value": "7981677 options"
            },
            {
              "key": "Exercisable—December 31, 2022",
              "value": "4313997 options"
            },
            {
              "key": "Options vested, or expected to vest—December 31, 2022",
              "value": "7981677 options"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 106,
          "title": "Restricted Stock Units RSUs Activity Summary",
          "data": [
            {
              "key": "Unvested—December 31, 2021",
              "value": "132,333 shares"
            },
            {
              "key": "Granted",
              "value": "131,205 shares"
            },
            {
              "key": "Vested",
              "value": "-38750 shares"
            },
            {
              "key": "Unvested—December 31, 2022",
              "value": "224788 shares"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 107,
          "title": "Employee Stock Purchase Plan and Contributions to Section 401(k) Plan",
          "data": [
            {
              "key": "ESPP Initial Shares Authorized",
              "value": "250,000 shares"
            },
            {
              "key": "ESPP Increase on January 1, 2023",
              "value": "1,767,411 shares"
            },
            {
              "key": "Shares Issued in 2022",
              "value": "28,999 shares"
            },
            {
              "key": "Shares Issued in 2021",
              "value": "26,878 shares"
            },
            {
              "key": "Stock-Based Compensation Expense for 2022",
              "value": "$166,000"
            },
            {
              "key": "Stock-Based Compensation Expense for 2021",
              "value": "$175,000"
            },
            {
              "key": "Stock-Based Compensation Expense for 2020",
              "value": "$203,000"
            },
            {
              "key": "401(k) Contributions for 2022",
              "value": "$712,000"
            },
            {
              "key": "401(k) Contributions for 2021",
              "value": "$444,000"
            },
            {
              "key": "401(k) Contributions for 2020",
              "value": "$250,000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 111,
          "title": "Exhibit 10.24 SYNDAX PHARMACEUTICALS, INC. AMENDED & RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY",
          "data": [
            {
              "key": "Effective Date",
              "value": "February 2, 2023"
            },
            {
              "key": "Non-Employee Directors Annual Base Cash Fee",
              "value": "$43,470"
            },
            {
              "key": "Annual Deferred Settlement Restricted Stock Units (Non-Chair)",
              "value": "16,000 shares (adjusted for stock splits, stock dividends, recapitalization, and similar events)"
            },
            {
              "key": "Annual Deferred Settlement Restricted Stock Units (Chair)",
              "value": "32,000 shares (adjusted for stock splits, stock dividends, recapitalization, and similar events)"
            },
            {
              "key": "Chair Annual Cash Retainer",
              "value": "$76,072"
            },
            {
              "key": "New Director Award",
              "value": "Options to purchase 35,000 shares vesting monthly over a three-year period"
            },
            {
              "key": "Committee Service Compensation",
              "value": "Audit committee: $10,867; Compensation committee: $8,150; Science & Technology committee: $8,150; Nominating and Corporate Governance committee: $5,434. Additional chair retainers: Audit committee: $21,735; Compensation committee: $16,300; Science & Technology committee: $16,300; Nominating and Corporate Governance committee: $10,867"
            },
            {
              "key": "Travel Expense Reimbursement",
              "value": "Directors are reimbursed for travel expenses incurred in connection with attendance at Board and committee meetings"
            },
            {
              "key": "Payment Frequency",
              "value": "All cash retainers are paid in equal quarterly installments"
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_rnd_investment_numbers": {
      "value": true,
      "elements": [
        {
          "type": "rnd_investment",
          "page": 5,
          "title": "Business Overview and Pipeline Strategy",
          "data": [
            {
              "key": "Company Description",
              "value": "A clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies."
            },
            {
              "key": "Lead Product Candidates",
              "value": "revumenib (SNDX-5613) and axatilimab (SNDX-6352)"
            },
            {
              "key": "Product Details",
              "value": "Revumenib is a potent, selective small molecule inhibitor of the menin-MLL binding interaction for treating genetically defined acute leukemias (KMT2Ar and NPM1 mutant AML). Axatilimab is a monoclonal antibody that blocks the CSF-1 receptor for treatment of chronic graft-versus-host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF)."
            },
            {
              "key": "Clinical Trials",
              "value": "Revumenib is under evaluation in the Phase 1/2 open-label AUGMENT-101 trial with a pivotal Phase 2 expansion in relapsed/refractory patients across KMT2Ar ALL, KMT2Ar AML, and NPM1c AML, including expansion into frontline and maintenance settings. Axatilimab has completed enrollment in the pivotal AGAVE-201 trial for cGVHD and is planned for a combination trial with ruxolitinib in steroid-naive cGVHD patients."
            },
            {
              "key": "Development Strategy",
              "value": "Leveraging technical, clinical, regulatory, and business expertise to license, acquire, and develop additional therapeutics to expand the pipeline, including strategic collaborations with partners like Incyte."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 6,
          "title": "Drug Development Pipeline and Mechanism Diagram",
          "data": [
            {
              "key": "Pipeline Table",
              "value": "The table outlines the drug development pipeline with details for drug candidates including Revumenib (a Menin inhibitor) with multiple clinical trials (AUGMENT-101 series, AUGMENT-102, BEAT-AML, INTERCEPT, Colorectal Cancer), Axatilimab (a CSF-1R mAB) with trial AGAVE-201, and Entinostat (Class 1 HDAC inhibitor). The table includes columns such as PreClin, Phase 1, Phase 2, Pivotal, and Indication(s) along with a development pipeline status overview."
            },
            {
              "key": "Mechanism Diagram",
              "value": "A scientific diagram illustrates the therapeutic mechanism of Revumenib. The left panel depicts the normal interaction between Menin and KMT2A* proteins leading to activation of HOX and MEIS genes (ON state) causing leukemia. The right panel shows the effect of Revumenib blocking the Menin-KMT2A* interaction, turning gene transcription OFF and leading to cell differentiation/apoptosis. Source: Adapted from Uckelmann HJ, et al. Presented at ASH Annual Meeting, 2018."
            },
            {
              "key": "Product Focus",
              "value": "Revumenib, the first clinical-stage product candidate, is a potent, orally active Menin inhibitor targeting acute leukemias driven by KMT2Ar and NPM1c mutations, aimed at R/R patient populations."
            },
            {
              "key": "Near-term Focus",
              "value": "The near-term objective is to rapidly establish proof-of-concept that revumenib is a targeted therapy offering meaningful clinical benefit for adult and pediatric R/R patients with mNPM1 and KMT2Ar, and ALL."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 9,
          "title": "Colorectal Cancer Treatment Advancements",
          "data": [
            {
              "key": "Cancer Type",
              "value": "Colorectal Cancer (CRC)"
            },
            {
              "key": "Cases in 2022",
              "value": "150,000 new cases"
            },
            {
              "key": "Deaths in 2022",
              "value": "52,000 deaths"
            },
            {
              "key": "Five-Year Survival Rate",
              "value": "65% (drops to 15% for metastatic CRC)"
            },
            {
              "key": "Chemotherapy Options",
              "value": "Stivarga®, Lonsurf®"
            },
            {
              "key": "Immunotherapy Options",
              "value": "Yervoy®, Keytruda®, Opdivo®"
            },
            {
              "key": "Targeted Agents",
              "value": "Avastin®, Cyramza®, Zaltrap®, Erbitux®, Vectibix®, Braftovi®"
            },
            {
              "key": "Target in Treatment Development",
              "value": "KMT2A"
            },
            {
              "key": "Experimental Drug",
              "value": "Axatilimab"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 12,
          "title": "License Agreements with Vitae Pharmaceuticals, Inc. and UCB",
          "data": [
            {
              "key": "Vitae Agreement - Agreement Name",
              "value": "AbbVie License Agreement with Vitae Pharmaceuticals, Inc."
            },
            {
              "key": "Vitae Agreement - Licensed Assets",
              "value": "Preclinical, orally-available, small molecule inhibitors targeting the interaction of menin with the MLL protein (Menin Assets)"
            },
            {
              "key": "Vitae Agreement - Development and Commercialization Responsibility",
              "value": "Sole responsibility for the development and commercialization of the Menin Assets"
            },
            {
              "key": "Vitae Agreement - Milestone Payment Cap",
              "value": "$99 million in one-time development and regulatory milestone payments"
            },
            {
              "key": "Vitae Agreement - Royalty Terms",
              "value": "Low single to low double-digit royalties on sales, with potential reductions under certain circumstances"
            },
            {
              "key": "Vitae Agreement - Sales-based Milestones",
              "value": "Up to $70.0 million in potential one-time, sales-based milestone payments based on annual sales thresholds"
            },
            {
              "key": "Vitae Agreement - Actual Milestone Payments",
              "value": "$8.0 million achieved overall (including $2.0 million in 2022) and an additional $2.0 million accrued expense in Q4 2022, paid in Q1 2023"
            },
            {
              "key": "Vitae Agreement - Termination Conditions",
              "value": "Either party may terminate for uncured material breach or insolvency; the Company may terminate at will with advance written notice; Vitae may terminate if a legal challenge to the licensed patent rights is instituted"
            },
            {
              "key": "UCB Agreement - Agreement Name",
              "value": "UCB License Agreement"
            },
            {
              "key": "UCB Agreement - Licensed Asset",
              "value": "UCB6352, referred to as axatilimab"
            },
            {
              "key": "UCB Agreement - Scope of Use",
              "value": "Worldwide, sublicensable, exclusive license for all human uses including treatment, prevention, and diagnostic applications"
            },
            {
              "key": "UCB Agreement - Development and Commercialization Responsibility",
              "value": "Sole responsibility for the development and commercialization of axatilimab"
            },
            {
              "key": "UCB Agreement - Milestone Payment Cap",
              "value": "Up to $119.5 million in one-time development and regulatory milestone payments"
            },
            {
              "key": "UCB Agreement - Royalty Terms",
              "value": "Low double-digit royalties on sales, subject to reduction under certain circumstances"
            },
            {
              "key": "UCB Agreement - Sales-based Milestones",
              "value": "Up to $250.0 million in potential one-time, sales-based milestone payments based on annual sales thresholds"
            },
            {
              "key": "UCB Agreement - Actual Milestone Payments",
              "value": "$2.0 million in 2020, $4.0 million in 2021 and $5.8 million milestone expense recognized in Q2 2022"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "rnd_investment",
          "page": 63,
          "title": "Research and Development Expenses Overview",
          "data": [
            {
              "key": "Expense Categories",
              "value": "Employee-related expenses (salaries, benefits, travel, non-cash stock-based compensation), manufacturing process-development, clinical supplies, technology-transfer expenses, license fees, milestone payments, consulting fees, allocated facilities and overhead expenses, and regulatory compliance costs."
            },
            {
              "key": "Cost Recognition",
              "value": "Internal and external R&D costs are expensed as incurred; cost-sharing amounts are recorded as reductions to R&D expenses; some development costs (e.g., clinical trials) are recognized based on progress metrics such as patient enrollment and clinical site activations."
            },
            {
              "key": "Cost Drivers",
              "value": "Factors influencing costs include per patient costs, number of patients, number of clinical sites, countries involved, patient enrollment duration, additional regulatory safety monitoring, and the efficacy and safety profile of product candidates."
            },
            {
              "key": "Investment Outlook",
              "value": "The company plans to continue significant spending on R&D. External spending is expected to grow at a higher rate than internal spending, while timelines and overall costs remain uncertain due to factors like clinical trial complexity and regulatory variables."
            },
            {
              "key": "General and Administrative",
              "value": "G&A expenses include employee-related costs (salaries, benefits, non-cash stock-based compensation, travel) for executives and support functions, along with facility-related, accounting, tax, legal, and consulting expenses."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 84,
          "title": "Audit Procedures for R&D and Clinical Cost Estimates",
          "data": [
            {
              "key": "Description",
              "value": "The page details activities related to recording expenses, prepayments, and accruals under the terms of agreements with CROs, with a focus on research and development expenses and clinical costs."
            },
            {
              "key": "Critical Audit Matter",
              "value": "Estimates for research and development expenses and clinical costs were identified as critical due to significant management judgment in determining prepaid or accrued costs."
            },
            {
              "key": "Management Judgment",
              "value": "High level of subjectivity in estimating accrued or prepaid costs and assessing progress toward completion of R&D activities and studies."
            },
            {
              "key": "Auditor Procedures",
              "value": "Procedures included testing internal controls, verifying completeness and accuracy of inputs through contract and communication inspection, and evaluating the reasonableness of assumptions regarding progress and incurred costs."
            },
            {
              "key": "Audit Details",
              "value": "Sample testing involved review of contracts, statements of work, actual invoicing and payment data, and inquiries with personnel overseeing research and development activities."
            },
            {
              "key": "Audit Report",
              "value": "Deloitte & Touche LLP, Boston, Massachusetts; report dated February 28, 2023."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 94,
          "title": "Research and Development Costs",
          "data": [
            {
              "key": "Development Milestone Payments",
              "value": "The Company evaluates whether milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method."
            },
            {
              "key": "Commercial Milestone Payments and Royalties",
              "value": "For arrangements that include sales-based royalties, the Company will recognize revenue when the related sales occur or when the performance obligation has been satisfied."
            },
            {
              "key": "Deferred Revenue",
              "value": "Deferred revenue arises from amounts received in advance of the culmination of the earnings process and is recognized as revenue in future periods."
            },
            {
              "key": "Research and Development Expenses",
              "value": "Research and development costs are expensed as incurred, including payroll and consulting costs, and are capitalized as a prepaid expense if paid in advance."
            },
            {
              "key": "Clinical Costs",
              "value": "Clinical study and trial costs are a component of research and development expenses."
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_new_product_launches": {
      "value": true,
      "elements": [
        {
          "type": "product_launch",
          "page": 8,
          "title": "Revumenib NDA Filing and Clinical Pipeline Update",
          "data": [
            {
              "key": "Drug Name",
              "value": "Revumenib"
            },
            {
              "key": "Indication",
              "value": "Treatment of R/R acute leukemia harboring a KMT2A rearrangement"
            },
            {
              "key": "Filing Strategy",
              "value": "Pool data from AUGMENT-101 cohorts (R/R KMT2Ar AML and R/R KMT2Ar ALL) for a single NDA"
            },
            {
              "key": "Enrollment Status",
              "value": "Sufficient enrollment in KMT2Ar acute leukemia cohort; NPM1 AML cohort enrollment expected in the second half of 2023"
            },
            {
              "key": "Timeline",
              "value": "Topline data expected in Q3 2023; NDA filing by end of 2023"
            },
            {
              "key": "Targeted Mutation/Mechanism",
              "value": "Targeting the menin-MLL interaction in MLLr leukemias and NPM1c AML"
            },
            {
              "key": "Image Metadata",
              "value": "Genetic diagram of MLL gene: Location 11q23, breakpoint ~6.5 kb, protein length 3969 amino acids, >90 known MLL fusions"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 10,
          "title": "Axatilimab Clinical Development and Trial Update",
          "data": [
            {
              "key": "Drug Candidate",
              "value": "Axatilimab"
            },
            {
              "key": "Indications",
              "value": "Advanced cGVHD, IPF, and other fibrotic diseases"
            },
            {
              "key": "Clinical Trials",
              "value": "Pivotal AGAVE-201 trial in cGVHD (enrollment complete as of November 3, 2022), planned Phase 2b trial for IPF, and a Phase 1 trial combining axatilimab with ruxolitinib in steroid-naive cGVHD"
            },
            {
              "key": "Endpoints",
              "value": "Primary endpoint: objective response rate based on NIH consensus criteria (cGVHD); Key secondary endpoints: duration of response, improvement in modified Lee Symptom Scale score; In IPF, change from baseline in forced vital capacity"
            },
            {
              "key": "Regulatory Milestones",
              "value": "FDA granted Orphan Drug Designation in March-April 2021; Expect topline data in mid-2023 and potential Biologics License Application submission by end of 2023"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 18,
          "title": "FDA Submission and Clinical Trials Overview",
          "data": [
            {
              "key": "FDA Submission",
              "value": "submission to the FDA of an NDA for a new drug product or a Biologics License Application, or BLA, for biologics."
            },
            {
              "key": "Application Review Timeline",
              "value": "determination by the FDA within 60 days of its receipt of an NDA or BLA to accept the application for filing and review."
            },
            {
              "key": "Inspection Requirements",
              "value": "satisfactory completion of an FDA inspection of the manufacturing facilities."
            },
            {
              "key": "Preclinical Stage",
              "value": "Before testing any compounds with potential therapeutic value in humans, the product candidate enters the preclinical testing stage."
            },
            {
              "key": "IND Submission Requirements",
              "value": "an IND must be submitted to the FDA prior to commencing first clinical trial."
            },
            {
              "key": "Phases of Clinical Trials",
              "value": "Human clinical trials are typically conducted in three sequential phases: Phase 1, Phase 2, Phase 3."
            },
            {
              "key": "Post-Market Studies",
              "value": "Post-approval studies, or Phase 4 clinical trials, may be required by the FDA as a condition of approval."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 19,
          "title": "Manufacturing Process and FDA Regulatory Review",
          "data": [
            {
              "key": "Clinical and Preclinical Studies",
              "value": "Concurrent with clinical trials, additional animal studies are conducted and detailed information about the chemistry and physical characteristics of the product candidate is developed."
            },
            {
              "key": "Manufacturing Process Requirements",
              "value": "A robust manufacturing process compliant with cGMP is required to consistently produce quality batches, including methods for testing identity, strength, quality, and purity, as well as validated packaging and stability studies."
            },
            {
              "key": "Regulatory Submission Process",
              "value": "For market approval in the United States, an NDA or BLA must be submitted with all relevant nonclinical and clinical data, including both positive and negative findings, along with detailed manufacturing and product information."
            },
            {
              "key": "FDA Review and Inspection",
              "value": "The FDA reviews submissions for completeness within 60 days, may grant priority review for serious conditions, and inspects manufacturing facilities and clinical sites to ensure compliance with cGMP and GCP."
            },
            {
              "key": "Approval Decision",
              "value": "Upon review, the FDA either approves the product or issues a complete response letter indicating required changes or additional data needed."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 33,
          "title": "Regulatory Approval and Manufacturing Challenges for Product Candidates",
          "data": [
            {
              "key": "Regulatory Approval Requirements",
              "value": "Facilities used by third-party manufacturers and Incyte must be approved by the FDA or relevant foreign regulatory agencies."
            },
            {
              "key": "Dependence on Third Parties",
              "value": "Reliance on third-party suppliers and manufacturers for clinical drug supplies."
            },
            {
              "key": "Impact of Regulatory Approval",
              "value": "Failure to meet regulatory requirements could impede the development, approval or marketing of product candidates."
            },
            {
              "key": "Post-Marketing Requirements",
              "value": "Products will be subject to ongoing regulatory requirements after approval."
            },
            {
              "key": "Manufacturing Compliance Checks",
              "value": "Continuous review and inspections by regulatory authorities for compliance with cGMP regulations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 34,
          "title": "Product Regulatory Compliance Risks",
          "data": [
            {
              "key": "regulatory_compliance",
              "value": "Manufacturing and promotional compliance with regulations is crucial for product commercialization."
            },
            {
              "key": "potential_penalties",
              "value": "Failure to comply may result in fines, injunctions, or withdrawal of regulatory approvals."
            },
            {
              "key": "off_label_promotions",
              "value": "Promotion for off-label uses can lead to government sanctions."
            },
            {
              "key": "false_claims_act",
              "value": "Engagement in false claims can lead to substantial legal liabilities."
            },
            {
              "key": "litigation_risks",
              "value": "Increased litigation risk associated with promotional practices."
            },
            {
              "key": "effects_on_business",
              "value": "Potential negative impacts on business operations and financial results."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 36,
          "title": "Overview of Competitive Landscape and Product Potential",
          "data": [
            {
              "key": "product_candidate",
              "value": "axatilimab"
            },
            {
              "key": "FDA_approved_competitors",
              "value": "ibrutinib (Imbruvica®), belomosidil (Rezurock®), ruxolitinib (Jakafi®)"
            },
            {
              "key": "indication",
              "value": "chronic graft versus host disease (cGVHD)"
            },
            {
              "key": "potential_first_therapy",
              "value": "revumenib for KMT2Ar ALL, KMT2Ar AML, NPM1 mutant AML"
            },
            {
              "key": "dependency",
              "value": "dependent on UCB Biopharma Sprl for license agreement compliance"
            },
            {
              "key": "competition",
              "value": "intense competition from existing and new drugs, especially with substantial resources"
            },
            {
              "key": "regulatory_approval_impact",
              "value": "faster approval of competitors' drugs could limit market acceptance of our candidates"
            },
            {
              "key": "business_plan_dependency",
              "value": "business plan dependent on successful commercialization of axatilimab"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 96,
          "title": "Incyte Collaboration",
          "data": [
            {
              "key": "Date of Agreement",
              "value": "September 2021"
            },
            {
              "key": "Payment Amount",
              "value": "$117 million"
            },
            {
              "key": "Future Milestones Potential",
              "value": "up to $220 million in development and regulatory milestones, up to $230 million in commercialization milestones"
            },
            {
              "key": "Royalty Percentages",
              "value": "mid-teens percentage in Europe and Japan, low double-digit percentage rest of the world"
            },
            {
              "key": "Common Stock Issued",
              "value": "1,421,523 shares"
            },
            {
              "key": "Total Cash Consideration",
              "value": "$152 million"
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_capital_expenditures": {
      "value": true,
      "elements": [
        {
          "type": "capital_expenditure",
          "page": 44,
          "title": "Forecast on Operating Expenses and Capital Requirements",
          "data": [
            {
              "key": "current_cash_position",
              "value": "sufficient to fund projected operating expenses and capital expenditures for at least the next 12 months"
            },
            {
              "key": "risk_of_additional_funding",
              "value": "may need additional funding to continue operations or develop new products"
            },
            {
              "key": "expected_increase_in_r_d_expenses",
              "value": "research and development expenses expected to increase substantially"
            },
            {
              "key": "impact_of_economic_conditions",
              "value": "global economic slowdown may cause capital consumption to be more rapid than anticipated"
            },
            {
              "key": "uncertainty_in_product_commercialization",
              "value": "unable to predict timing or amount of expenses related to commercialization"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_expenditure",
          "page": 93,
          "title": "Property and Equipment and Impairment of Long-Lived Assets",
          "data": [
            {
              "key": "Property and Equipment",
              "value": "Recorded at cost; Depreciation via straight-line method; Capitalized major replacements and improvements."
            },
            {
              "key": "Depreciation Method",
              "value": "Straight-line method over 3 to 5 years."
            },
            {
              "key": "Impairment of Long-Lived Assets",
              "value": "Reviewed for impairment; comparison of carrying amounts to undiscounted expected future cash flows."
            },
            {
              "key": "Recognition of Impairment",
              "value": "Difference between carrying value and fair value if impairment detected."
            },
            {
              "key": "Debt Issuance Costs",
              "value": "Payments recognized as interest expense using effective interest method."
            },
            {
              "key": "Derivative Financial Instruments",
              "value": "Accounted for as equity or liabilities depending on characteristics."
            },
            {
              "key": "Revenue Recognition",
              "value": "Recognized upon customer control of goods or services; follows five-step model under ASC 606."
            },
            {
              "key": "Intellectual Property Licensing Revenue",
              "value": "Recognized as licenses are transferred to customers."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_financial_performance_indicators": {
      "value": true,
      "elements": [
        {
          "type": "financial_performance",
          "page": 59,
          "title": "COMPARISON OF 5 YEAR CUMULATIVE TOTAL RETURN Among Syndax Pharmaceuticals, Inc., the NASDAQ Composite Index and the NASDAQ Biotechnology Index",
          "data": [
            {
              "key": "Chart Type",
              "value": "Line chart showing cumulative total return over 5 years"
            },
            {
              "key": "Baseline",
              "value": "$100 invested on 12/31/17 in stock or index, including reinvestment of dividends"
            },
            {
              "key": "Timeframe",
              "value": "Fiscal year ending December 31"
            },
            {
              "key": "Y-axis",
              "value": "Value in dollars"
            },
            {
              "key": "Lines",
              "value": "Syndax Pharmaceuticals, Inc.; NASDAQ Composite; NASDAQ Biotechnology"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 60,
          "title": "Item 6. [Reserved]",
          "data": [
            {
              "key": "Reserved",
              "value": "56"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 61,
          "title": "Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations",
          "data": [
            {
              "key": "Overview",
              "value": "Clinical-stage biopharmaceutical company developing innovative cancer therapies with two lead product candidates: revumenib (SNDX-5613) and axatilimab (SNDX-6352)"
            },
            {
              "key": "Forward Looking Statements",
              "value": "Contains forward-looking statements with risks and uncertainties, including those related to risk factors, global economic slowdown, inflation, interest rates, and geopolitical events."
            },
            {
              "key": "Financial Results",
              "value": "For the years ended December 31, 2022 and 2020, net losses of $149.3 million and $73.2 million were reported respectively, while a net profit of $24.9 million was reported for the year ended December 31, 2021."
            },
            {
              "key": "Accumulated Deficit as of December 31, 2022",
              "value": "$693.0 million (includes non-cash charges for stock-based compensation, preferred stock accretion, and extinguishment charges)"
            },
            {
              "key": "Cash and Investments as of December 31, 2022",
              "value": "$481.3 million in cash, cash equivalents and short-term/long-term investments"
            },
            {
              "key": "Risk Factors",
              "value": "Risks include global economic slowdown, disruption in healthcare systems, inflationary pressures impacting costs, rising interest rates, potential recession, and volatility in capital markets."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 64,
          "title": "Discussion on Expense Forecasts, Interest, and Revenue Recognition",
          "data": [
            {
              "key": "Future Expense Guidance",
              "value": "Anticipate that general and administrative expenses will increase as headcount is expanded to support continued research and development and the potential commercialization of product candidates."
            },
            {
              "key": "Payroll and Commercial Operations",
              "value": "If regulatory approval appears likely, an increase in payroll and related expenses is expected due to preparation for commercial operations, particularly in sales and marketing."
            },
            {
              "key": "Interest Expense",
              "value": "Primarily related to term loans, operational and capital leases."
            },
            {
              "key": "Interest Income",
              "value": "Income generated from cash, cash equivalents, and short- and long-term investments."
            },
            {
              "key": "Revenue Recognition",
              "value": "Revenues from contracts with customers, including license agreements with variable consideration components, are discussed along with related performance obligations."
            },
            {
              "key": "Accounting Policies and Estimates",
              "value": "Discussion includes critical accounting estimates, recent accounting pronouncements, and judgments based on historical experience for preparing financial statements."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 65,
          "title": "Revenue Recognition and Accrued R&D Expenses",
          "data": [
            {
              "key": "Variable consideration method",
              "value": "Utilized the most likely amount method; included in the transaction price if it is probable that a significant future reversal of cumulative revenue will not occur."
            },
            {
              "key": "Performance obligations assessment",
              "value": "Evaluated from the customer's perspective. For the Incyte Collaboration Agreement, the license was a distinct performance obligation; for the KKC Agreement, the performance obligations were not distinct at contract inception."
            },
            {
              "key": "Incyte Collaboration Agreement revenue (Dec 31, 2021)",
              "value": "$126.6 million recognized as license revenue."
            },
            {
              "key": "KKC Agreement revenue details",
              "value": "$13.3 million initially recorded with $12.4 million recognized in the third quarter of 2021 following cancellation of the entinostat program."
            },
            {
              "key": "Accrued R&D Expense estimation",
              "value": "Estimates are based on reviewing contracts, vendor agreements, clinical study fees, CRO fees, and services performed, with adjustments made if actual service timing or effort deviates from estimates."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 66,
          "title": "Financial Performance Summary & Research and Development Expenses Comparison",
          "data": [
            {
              "key": "Table Title",
              "value": "Financial Performance Summary"
            },
            {
              "key": "License fees 2022",
              "value": "0"
            },
            {
              "key": "License fees 2021",
              "value": "139709"
            },
            {
              "key": "Total revenues 2022",
              "value": "0"
            },
            {
              "key": "Total revenues 2021",
              "value": "139709"
            },
            {
              "key": "Research and development 2022",
              "value": "118499"
            },
            {
              "key": "Research and development 2021",
              "value": "88248"
            },
            {
              "key": "General and administrative 2022",
              "value": "33258"
            },
            {
              "key": "General and administrative 2021",
              "value": "25241"
            },
            {
              "key": "Total operating expenses 2022",
              "value": "151757"
            },
            {
              "key": "Total operating expenses 2021",
              "value": "113489"
            },
            {
              "key": "(Loss) Income from operations 2022",
              "value": "-151757"
            },
            {
              "key": "(Loss) Income from operations 2021",
              "value": "26220"
            },
            {
              "key": "Net (loss) income 2022",
              "value": "-149338"
            },
            {
              "key": "Net (loss) income 2021",
              "value": "24926"
            },
            {
              "key": "Additional Note",
              "value": "License fees in 2022 were not recognized, while 2021 recognized fees from Incyte and KKC agreements. Operating expenses increased and net income swung from a profit to a significant loss."
            },
            {
              "key": "R&D Expenses Table Title",
              "value": "Research and Development Expenses Comparison (in thousands)"
            },
            {
              "key": "External R&D Expenses 2022",
              "value": "89788"
            },
            {
              "key": "External R&D Expenses 2021",
              "value": "68468"
            },
            {
              "key": "Internal R&D Expenses 2022",
              "value": "28711"
            },
            {
              "key": "Internal R&D Expenses 2021",
              "value": "19780"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 67,
          "title": "Financial Performance and Liquidity Overview",
          "data": [
            {
              "key": "General and Administrative Expenses Increase",
              "value": "Increased by $8.0 million (32%) to $33.3 million from $25.2 million for the year ended December 31, 2022"
            },
            {
              "key": "Employee-Related Expenses Increase",
              "value": "Employee-related expenses increased by $5.3 million, including $4.3 million for salaries and benefits and $1.0 million for stock compensation expense"
            },
            {
              "key": "Professional Fees Increase",
              "value": "Increased by $1.4 million"
            },
            {
              "key": "Other Expenses Increase",
              "value": "Increased by $1.3 million, with travel and entertainment up $1.1 million and rent and utilities up $0.2 million"
            },
            {
              "key": "Interest Income Increase",
              "value": "Interest income increased by $5.5 million, primarily due to higher interest rates on investments"
            },
            {
              "key": "Interest Expense Increase",
              "value": "Increased primarily due to the amended term loan and loan payoff during the third quarter of 2022"
            },
            {
              "key": "Other (Expense) Income Decrease",
              "value": "Decreased by $0.5 million, primarily due to changes in the fair value of the derivative liability under the Incyte Collaboration Agreement"
            },
            {
              "key": "Liquidity Position",
              "value": "As of December 31, 2022, cash, cash equivalents and investments totaled $481.3 million, sufficient to fund operating expenses and capital expenditure requirements for at least the next 12 months"
            },
            {
              "key": "Loan and Security Agreement Termination",
              "value": "Terminated in September 2022 with a prepayment of $21.5 million, including a $1.0 million end-of-term fee and a $0.4 million prepayment fee; Hercules released all security interests"
            },
            {
              "key": "Future Funding Requirements",
              "value": "Available cash and investments are expected to fund existing and planned cash requirements, including compensation, research and development, and clinical costs"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 69,
          "title": "Lease Commitments Schedule",
          "data": [
            {
              "key": "Table Title",
              "value": "Lease Commitments Schedule"
            },
            {
              "key": "Table Summary",
              "value": "The table breaks down lease commitments for office space and equipment. Total lease obligations are $1,373,000, with $574,000 due within 1 year and $797,000 due in years 2-4. Operating leases for office space constitute the majority ($1,351,000) while capital leases for office equipment account for $22,000."
            },
            {
              "key": "Lease Narrative",
              "value": "In August 2021, a 36‑month extension was signed for the office space in Waltham, MA; and in August 2022, a similar 36‑month extension was signed for the office space in New York, NY. In January 2022, two four‑year non‑cancelable leases for office equipment were entered into as capital leases, with the leased assets included in property and equipment, net. The narrative also highlights that lease payment obligations exclude common area maintenance charges and real estate taxes, and it discusses the company’s ongoing operating losses, accumulated deficit, and the associated risks of potentially dilutive future capital raises."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 69,
          "title": "Cash Flow Summary",
          "data": [
            {
              "key": "Table Title",
              "value": "Cash Flow Summary"
            },
            {
              "key": "Operating Cash Flow",
              "value": "2022: -$433,675k; 2021: $29,131k; 2020: -$71,260k"
            },
            {
              "key": "Investing Cash Flow",
              "value": "2022: -$186,188k; 2021: -$40,873k; 2020: -$142,530k"
            },
            {
              "key": "Financing Cash Flow",
              "value": "2022: $172,254k; 2021: $118,464k; 2020: $304,424k"
            },
            {
              "key": "Net Cash Change",
              "value": "2022: -$147,609k; 2021: $106,722k; 2020: $90,634k"
            },
            {
              "key": "Table Summary",
              "value": "The cash flow summary shows significant negative operating cash flow in 2022, reversing the positive results seen in 2021 and 2020. While financing activities remain positive each year, investing activities have consistently been negative, leading to a decline in overall cash and cash equivalents in 2022."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 70,
          "title": "Financial Performance Overview of Cash Flows",
          "data": [
            {
              "key": "Net cash used in operating activities (2022)",
              "value": "$133.7 million"
            },
            {
              "key": "Net loss (2022)",
              "value": "$149.3 million"
            },
            {
              "key": "Stock-based compensation (2022)",
              "value": "$16.0 million"
            },
            {
              "key": "Net cash provided by operating activities (2021)",
              "value": "$29.1 million"
            },
            {
              "key": "Net income (2021)",
              "value": "$24.9 million"
            },
            {
              "key": "Net cash used in investing activities (2022)",
              "value": "$186.2 million"
            },
            {
              "key": "Net cash used in investing activities (2021)",
              "value": "$40.9 million"
            },
            {
              "key": "Net cash provided by financing activities (2022)",
              "value": "$172.3 million"
            },
            {
              "key": "Net cash provided by financing activities (2021)",
              "value": "$118.5 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 72,
          "title": "Evaluation of Disclosure Controls and Procedures",
          "data": [
            {
              "key": "Evaluation Date",
              "value": "December 31, 2022"
            },
            {
              "key": "Control Effectiveness",
              "value": "Effective at the reasonable assurance level"
            },
            {
              "key": "Management Responsibility",
              "value": "Establishment and maintenance of internal control over financial reporting"
            },
            {
              "key": "Internal Control Limitation",
              "value": "May not prevent or detect misstatements"
            },
            {
              "key": "Assessment Methodology",
              "value": "Criteria set by COSO"
            },
            {
              "key": "Attestation Firm",
              "value": "Deloitte & Touche LLP"
            },
            {
              "key": "Attestation Date",
              "value": "December 31, 2022"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 73,
          "title": "Audit Report on Internal Control over Financial Reporting",
          "data": [
            {
              "key": "Internal Control Changes",
              "value": "No change in internal control over financial reporting occurred during the fiscal quarter ended December 31, 2022."
            },
            {
              "key": "Audit Opinion",
              "value": "The independent registered public accounting firm expressed an unqualified opinion that effective internal control over financial reporting was maintained, in all material respects, as of December 31, 2022."
            },
            {
              "key": "Fiscal Period",
              "value": "Fiscal quarter and year ended December 31, 2022"
            },
            {
              "key": "Standards & Frameworks",
              "value": "Internal Control—Integrated Framework (2013) by COSO and PCAOB auditing standards"
            },
            {
              "key": "Financial Statements",
              "value": "Consolidated financial statements for the year ended December 31, 2022 received an unqualified audit opinion."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 82,
          "title": "Financial Statements Table of Contents",
          "data": [
            {
              "key": "Report of Independent Registered Public Accounting Firm (PCAOB ID 34)",
              "value": "F2"
            },
            {
              "key": "Consolidated Balance Sheets as of December 31, 2022 and 2021",
              "value": "F-4"
            },
            {
              "key": "Consolidated Statements of Operations for the Years Ended December 31, 2022, 2021 and 2020",
              "value": "F-5"
            },
            {
              "key": "Consolidated Statements of Comprehensive (Loss) Income for the Years Ended December 31, 2022, 2021 and 2020",
              "value": "F-6"
            },
            {
              "key": "Consolidated Statements of Stockholders' Equity for the Years Ended December 31, 2022, 2021 and 2020",
              "value": "F-7"
            },
            {
              "key": "Consolidated Statements of Cash Flows for the Years Ended December 31, 2022, 2021 and 2020",
              "value": ""
            },
            {
              "key": "Notes to Consolidated Financial Statements",
              "value": "F-10"
            },
            {
              "key": "Summary",
              "value": "This table appears to be a table of contents for a financial report, listing various consolidated financial statements and their corresponding page numbers. The documents cover the fiscal years 2020-2022 and include standard financial reports such as balance sheets, operations statements, comprehensive income statements, stockholders' equity statements, cash flow statements, and accompanying notes."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 83,
          "title": "REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM",
          "data": [
            {
              "key": "Company",
              "value": "Syndax Pharmaceuticals, Inc."
            },
            {
              "key": "Reporting Period",
              "value": "As of December 31, 2022 and 2021; Three-year period ended December 31, 2022"
            },
            {
              "key": "Audit Opinion",
              "value": "The financial statements present fairly, in all material respects, the financial position of the Company and the results of its operations and cash flows for the periods audited, in conformity with GAAP."
            },
            {
              "key": "Basis for Opinion",
              "value": "The financial statements are the responsibility of the Company's management. The audits were conducted in accordance with PCAOB standards, including risk assessment, evaluation of accounting principles and estimates, and review of internal control over financial reporting."
            },
            {
              "key": "Critical Audit Matter",
              "value": "Prepaid and Accrued Clinical Costs – Involving estimates related to expenses for clinical trials and studies as disclosed in Notes 3 and 11. This matter required especially challenging, subjective, or complex judgments."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 85,
          "title": "Balance Sheet",
          "data": [
            {
              "key": "Reporting Date",
              "value": "December 31, 2022"
            },
            {
              "key": "Total Current Assets",
              "value": "489,786"
            },
            {
              "key": "Total Assets",
              "value": "497,236"
            },
            {
              "key": "Total Current Liabilities",
              "value": "29,065"
            },
            {
              "key": "Total Liabilities",
              "value": "29,787"
            },
            {
              "key": "Total Stockholders' Equity",
              "value": "467,449"
            },
            {
              "key": "Total Liabilities and Stockholders' Equity",
              "value": "497,236"
            },
            {
              "key": "Summary",
              "value": "The balance sheet compares two periods. Notable figures include total assets of 497,236, current assets of 489,786, and a strong equity base of 467,449, with a decrease in total liabilities from the previous period."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 86,
          "title": "SYNDAX PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS",
          "data": [
            {
              "key": "License fees 2022",
              "value": "0"
            },
            {
              "key": "License fees 2021",
              "value": "139,709"
            },
            {
              "key": "License fees 2020",
              "value": "1,517"
            },
            {
              "key": "Total revenues 2022",
              "value": "0"
            },
            {
              "key": "Total revenues 2021",
              "value": "139,709"
            },
            {
              "key": "Total revenues 2020",
              "value": "1,517"
            },
            {
              "key": "Research and development 2022",
              "value": "118,499"
            },
            {
              "key": "Research and development 2021",
              "value": "88,248"
            },
            {
              "key": "Research and development 2020",
              "value": "50,435"
            },
            {
              "key": "General and administrative 2022",
              "value": "33,258"
            },
            {
              "key": "General and administrative 2021",
              "value": "25,241"
            },
            {
              "key": "General and administrative 2020",
              "value": "22,505"
            },
            {
              "key": "Total operating expenses 2022",
              "value": "151,757"
            },
            {
              "key": "Total operating expenses 2021",
              "value": "113,489"
            },
            {
              "key": "Total operating expenses 2020",
              "value": "72,940"
            },
            {
              "key": "(Loss) income from operations 2022",
              "value": "-151,757"
            },
            {
              "key": "(Loss) income from operations 2021",
              "value": "26,220"
            },
            {
              "key": "(Loss) income from operations 2020",
              "value": "-71,423"
            },
            {
              "key": "Net (loss) income 2022",
              "value": "-149,338"
            },
            {
              "key": "Net (loss) income 2021",
              "value": "24,926"
            },
            {
              "key": "Net (loss) income 2020",
              "value": "-73,158"
            },
            {
              "key": "Basic (loss) earnings per share 2022",
              "value": "-2.46"
            },
            {
              "key": "Basic (loss) earnings per share 2021",
              "value": "0.48"
            },
            {
              "key": "Basic (loss) earnings per share 2020",
              "value": "-1.87"
            },
            {
              "key": "Summary",
              "value": "This table presents a three-year financial summary from 2020 to 2022. The company experienced significant fluctuations in performance, with 2021 being the only profitable year showing net income of $24,926 and earnings per share of $0.48. In 2022, the company reported a substantial loss of $149,338 with operating expenses increasing to $151,757, primarily driven by higher R&D costs. Revenue generation was inconsistent, with 2021 showing peak license fees of $139,709. The company's R&D expenses have shown a consistent upward trend, increasing from $50,435 in 2020 to $118,499 in 2022, suggesting significant investment in development activities."
            },
            {
              "key": "Notes",
              "value": "The accompanying notes are an integral part of these consolidated financial statements. F-5"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 87,
          "title": "Net Income and Comprehensive Income Statement",
          "data": [
            {
              "key": "2022",
              "value": "Net Income: -149338, Unrealized Gains/Losses: -851, Comprehensive Income: -150189"
            },
            {
              "key": "2021",
              "value": "Net Income: 24926, Unrealized Gains/Losses: 49, Comprehensive Income: 24975"
            },
            {
              "key": "2020",
              "value": "Net Income: -73158, Unrealized Gains/Losses: -4, Comprehensive Income: -73162"
            },
            {
              "key": "Summary",
              "value": "The table shows financial performance across three years (2020-2022) with significant volatility. Despite a profitable year in 2021, there were losses in 2020 and 2022. Comprehensive income closely mirrors net income, affected by small unrealized gains/losses."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 89,
          "title": "Cash Flow Statement",
          "data": [
            {
              "key": "Net (loss) income 2022",
              "value": "-149338"
            },
            {
              "key": "Net (loss) income 2021",
              "value": "24926"
            },
            {
              "key": "Net (loss) income 2020",
              "value": "-73158"
            },
            {
              "key": "Depreciation 2022",
              "value": "33"
            },
            {
              "key": "Depreciation 2021",
              "value": "43"
            },
            {
              "key": "Depreciation 2020",
              "value": "89"
            },
            {
              "key": "Stock-based compensation 2022",
              "value": "16019"
            },
            {
              "key": "Stock-based compensation 2021",
              "value": "13317"
            },
            {
              "key": "Stock-based compensation 2020",
              "value": "9057"
            },
            {
              "key": "Net cash (used in) provided by operating activities 2022",
              "value": "-133675"
            },
            {
              "key": "Net cash (used in) provided by operating activities 2021",
              "value": "29131"
            },
            {
              "key": "Net cash (used in) provided by operating activities 2020",
              "value": "-71260"
            },
            {
              "key": "Net cash used in investing activities 2022",
              "value": "-186188"
            },
            {
              "key": "Net cash used in investing activities 2021",
              "value": "-40873"
            },
            {
              "key": "Net cash used in investing activities 2020",
              "value": "-142530"
            },
            {
              "key": "Net cash provided by financing activities 2022",
              "value": "172254"
            },
            {
              "key": "Net cash provided by financing activities 2021",
              "value": "118464"
            },
            {
              "key": "Net cash provided by financing activities 2020",
              "value": "304424"
            },
            {
              "key": "Cash, cash equivalents and restricted cash - end of year 2022",
              "value": "74471"
            },
            {
              "key": "Cash, cash equivalents and restricted cash - end of year 2021",
              "value": "222080"
            },
            {
              "key": "Cash, cash equivalents and restricted cash - end of year 2020",
              "value": "115358"
            },
            {
              "key": "Summary",
              "value": "This is a cash flow statement covering years 2020-2022. The company experienced significant fluctuations in its financial position, with a notable net loss of 149,338 in 2022 compared to a profit of 24,926 in 2021. Operating activities showed negative cash flow in 2022 (-133,675) and 2020 (-71,260), with a positive flow only in 2021. The company maintained strong financing activities, raising substantial cash through various financing mechanisms. Despite negative operating and investing cash flows in 2022, the company maintained a positive cash balance, though declining from 222,080 in 2021 to 74,471 in 2022."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 89,
          "title": "Cash and Cash Equivalents Statement",
          "data": [
            {
              "key": "Cash and cash equivalents 2022",
              "value": "74356"
            },
            {
              "key": "Cash and cash equivalents 2021",
              "value": "115243"
            },
            {
              "key": "Cash and cash equivalents 2020",
              "value": "221965"
            },
            {
              "key": "Restricted cash 2022",
              "value": "115"
            },
            {
              "key": "Restricted cash 2021",
              "value": "115"
            },
            {
              "key": "Restricted cash 2020",
              "value": "115"
            },
            {
              "key": "Cash, cash equivalents and restricted cash 2022",
              "value": "74471"
            },
            {
              "key": "Cash, cash equivalents and restricted cash 2021",
              "value": "222080"
            },
            {
              "key": "Cash, cash equivalents and restricted cash 2020",
              "value": "115358"
            },
            {
              "key": "Summary",
              "value": "This table shows the cash position over three years (2020-2022). There is a significant decrease in cash and cash equivalents from 221,965 in 2020 to 74,356 in 2022. Restricted cash remained constant at 115 across all years. The total cash position (including restricted cash) decreased from 115,358 in 2020 to 74,471 in 2022, showing a downward trend in the company's liquid assets."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 90,
          "title": "Supplemental disclosures of cash flow information (Note 17)",
          "data": [
            {
              "key": "Note",
              "value": "The accompanying notes are an integral part of these consolidated financial statements"
            },
            {
              "key": "Reference",
              "value": "F-9"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 92,
          "title": "Summary of Significant Accounting Policies",
          "data": [
            {
              "key": "Estimates and Assumptions",
              "value": "The Company makes estimates and assumptions that affect reported amounts and disclosures in the financial statements."
            },
            {
              "key": "Cash Equivalents",
              "value": "Includes all highly liquid investments maturing within 90 days."
            },
            {
              "key": "Restricted Cash",
              "value": "All cash pledged as collateral to secure long-term obligations."
            },
            {
              "key": "Marketable Securities",
              "value": "Classified as available-for-sale and reported at fair value."
            },
            {
              "key": "Segment Reporting",
              "value": "The Company has one operating segment."
            },
            {
              "key": "Concentrations of Credit Risk",
              "value": "Concentrations in cash and investments deposited in two financial institutions."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 101,
          "title": "Fair Value Measurements",
          "data": [
            {
              "key": "Date",
              "value": "December 31, 2022"
            },
            {
              "key": "Total Assets",
              "value": "$481,271"
            },
            {
              "key": "Cash Equivalents",
              "value": "$74,356"
            },
            {
              "key": "Short-term Investments",
              "value": "$401,446"
            },
            {
              "key": "Total Liabilities",
              "value": "$187"
            },
            {
              "key": "Balance Sheet Date",
              "value": "December 31, 2021"
            },
            {
              "key": "Total Assets 2021",
              "value": "$439,935"
            },
            {
              "key": "Derivative Liability",
              "value": "$187"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 103,
          "title": "Prepaid expenses and other current assets",
          "data": [
            {
              "key": "Prepaid insurance",
              "value": "692"
            },
            {
              "key": "Interest receivable on investments",
              "value": "583"
            },
            {
              "key": "Prepaid subscriptions",
              "value": "446"
            },
            {
              "key": "Other",
              "value": "194"
            },
            {
              "key": "Total prepaid expenses and other current assets",
              "value": "1915"
            },
            {
              "key": "2021 Total",
              "value": "1451"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 103,
          "title": "Accrued Expenses and Other Current Liabilities",
          "data": [
            {
              "key": "Accrued clinical study and trial costs",
              "value": "14375"
            },
            {
              "key": "Accrued compensation and related costs",
              "value": "5945"
            },
            {
              "key": "Accrued professional fees",
              "value": "1352"
            },
            {
              "key": "Accrued milestone costs",
              "value": "2000"
            },
            {
              "key": "Other",
              "value": "604"
            },
            {
              "key": "Total accrued expense and other current liabilities",
              "value": "24276"
            },
            {
              "key": "2021 Total",
              "value": "14465"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 103,
          "title": "Common Stock and Financing Activities",
          "data": [
            {
              "key": "Shares authorized",
              "value": "100,000,000"
            },
            {
              "key": "Common shares sold in 2022",
              "value": "1,111,111"
            },
            {
              "key": "Net proceeds from common shares (2022)",
              "value": "19.4 million"
            },
            {
              "key": "Pre-funded warrants issued",
              "value": "1,142,856"
            },
            {
              "key": "Net proceeds from December 2021 offering",
              "value": "81.2 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 108,
          "title": "Income Taxes and Deferred Tax Assets Details",
          "data": [
            {
              "key": "Pre-payment fee",
              "value": "Included as part of interest expense ($0.4 million) in 2022; noted in the context of the Amended Loan Agreement termination."
            },
            {
              "key": "Loan Agreement Termination",
              "value": "The Amended Loan Agreement was fully terminated as of September 23, 2022 with Hercules releasing all security interests held on the Company's assets."
            },
            {
              "key": "Interest Expense",
              "value": "For the years ended December 31, 2022 and 2021, the Company recognized $2.1 million (including the pre-payment fee) and $1.9 million respectively as interest expense related to the Initial Advance."
            },
            {
              "key": "Income Tax Rate Reconciliation",
              "value": "A table details reconciliation for the years 2020-2022, showing a constant federal statutory rate of 21.0%, with additional adjustments including state taxes, credit carryovers, non-deductible expenses, and significant changes in valuation allowance."
            },
            {
              "key": "Deferred Tax Assets (Liabilities)",
              "value": "A separate table compares key components for 2021 and 2022, listing net operating loss carryforwards, research and development credits, capitalized start-up costs, capitalized R&D costs, and other items. Full valuation allowances result in net deferred tax assets of zero."
            },
            {
              "key": "Valuation Allowance Adjustments",
              "value": "The valuation allowance increased by $35.9 million in 2022 (driven primarily by increases in deferred tax assets) and decreased by $4.8 million in 2021."
            },
            {
              "key": "Net Operating Losses (NOLs)",
              "value": "As of December 31, 2022, the Company held approximately $99.6 million in federal NOLs and $42.8 million in state NOLs, with portions of the NOLs set to expire starting in 2026."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 109,
          "title": "Tax Disclosures & Unrecognized Tax Benefit Reconciliation",
          "data": [
            {
              "key": "Federal Research Credits",
              "value": "$5.7 million as of December 31, 2022"
            },
            {
              "key": "State Research Credits",
              "value": "$3.2 million as of December 31, 2022"
            },
            {
              "key": "Deferred Tax Asset",
              "value": "$48.9 million (including $22.2 million related to TCJA-required capitalized expenses)"
            },
            {
              "key": "Unrecognized Tax Benefits (End-of-Year 2022)",
              "value": "$143 million (down from $163 million, with a $20 million decrease in prior period positions)"
            },
            {
              "key": "Net Operating Loss Carryforward Impact",
              "value": "Future tax benefit realization may be limited by ownership changes and statutory limitations"
            },
            {
              "key": "Ownership Change Dates",
              "value": "March 30, 2007; August 21, 2015; May 4, 2020"
            },
            {
              "key": "Legislative References",
              "value": "CARES Act; Tax Cuts and Jobs Act of 2017 (TCJA)"
            },
            {
              "key": "Tax Examination Status",
              "value": "All tax years since inception are open to examination; currently not under examination"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 110,
          "title": "Licensing Agreements and Supplemental Cash Flow Information",
          "data": [
            {
              "key": "Product",
              "value": "axatilimab"
            },
            {
              "key": "Co-promotion Right",
              "value": "The Company has the right to co-promote the product with Incyte."
            },
            {
              "key": "Incyte Payment",
              "value": "Non-refundable cash payment of $117 million in exchange for co-promotion rights."
            },
            {
              "key": "Incyte Equity Investment",
              "value": "$35 million equity investment by Incyte."
            },
            {
              "key": "Incyte Development Cost Share",
              "value": "Company is responsible for 45% of development costs for global and U.S. clinical trials."
            },
            {
              "key": "Eddingpharm Agreement",
              "value": "In April 2013, the Company entered into a License and Development Agreement and a Series B-1 Purchase Agreement with Eddingpharm for rights to develop and commercialize entinostat in China and other Asian countries."
            },
            {
              "key": "Eddingpharm Payment",
              "value": "Eddingpharm purchased $5.0 million of Series B-1 and agreed to contingent milestone and royalty payments based on revenue targets."
            },
            {
              "key": "Supplemental Cash Flow Information",
              "value": "Table discloses Interest paid: $1,631k (2020), $1,997k (2021), $2,059k (2022); Issuance costs: $43k (2020), $134k (2021), $131k (2022)."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 113,
          "title": "CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM",
          "data": [
            {
              "key": "Firm",
              "value": "Deloitte & Touche LLP"
            },
            {
              "key": "Location",
              "value": "Boston, Massachusetts"
            },
            {
              "key": "Consent Date",
              "value": "February 28, 2023"
            },
            {
              "key": "Registration Statements",
              "value": "333-254661 on Form S-3; 333-210412, 333-220172, 333-226678, 333-233083, 333-241654, 333-258628, 333-263185 on Form S-8"
            },
            {
              "key": "Company",
              "value": "Syndax Pharmaceuticals, Inc. and subsidiaries"
            },
            {
              "key": "Financial Reporting",
              "value": "Relating to the financial statements and the effectiveness of internal control over financial reporting"
            },
            {
              "key": "Annual Report",
              "value": "Form 10-K for the year ended December 31, 2022"
            },
            {
              "key": "Exhibit",
              "value": "Exhibit 23.1"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 114,
          "title": "CERTIFICATIONS",
          "data": [
            {
              "key": "Report Name",
              "value": "Annual Report on Form 10-K"
            },
            {
              "key": "Company",
              "value": "Syndax Pharmaceuticals, Inc."
            },
            {
              "key": "Certifier",
              "value": "Michael A. Metzger"
            },
            {
              "key": "Title",
              "value": "Chief Executive Officer (Principal Executive Officer)"
            },
            {
              "key": "Certification Date",
              "value": "February 28, 2023"
            },
            {
              "key": "Certification Summary",
              "value": "Certifies that the annual report contains no untrue or misleading statements of material fact, and that the financial statements fairly present the financial condition, results of operations, and cash flows, with effective internal controls over financial reporting."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 115,
          "title": "CERTIFICATIONS",
          "data": [
            {
              "key": "Certifier Name",
              "value": "Keith A. Goldan"
            },
            {
              "key": "Position",
              "value": "Chief Financial Officer (Principal Financial Officer)"
            },
            {
              "key": "Certification Date",
              "value": "February 28, 2023"
            },
            {
              "key": "Company",
              "value": "Syndax Pharmaceuticals, Inc."
            },
            {
              "key": "Report",
              "value": "Annual Report on Form 10-K"
            },
            {
              "key": "Exhibit",
              "value": "Exhibit 31.2"
            },
            {
              "key": "Summary",
              "value": "The certifier confirms that the report contains no material misstatements or omissions, that the financial statements fairly present the financial condition, results of operations, and cash flows, and that appropriate internal controls and disclosure procedures are in place and effective."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 116,
          "title": "CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002",
          "data": [
            {
              "key": "Legislative References",
              "value": "18 U.S.C. § 1350; Section 906 of the Sarbanes-Oxley Act of 2002; Rule 13a-14(b) of the Securities Exchange Act of 1934"
            },
            {
              "key": "Document Certification",
              "value": "The Annual Report on Form 10-K for the year ended December 31, 2022 is certified as fully compliant with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act and fairly presents the financial condition and results of operations."
            },
            {
              "key": "Certified By - CEO",
              "value": "Michael A. Metzger, Chief Executive Officer and Director of Syndax Pharmaceuticals, Inc."
            },
            {
              "key": "Certified By - CFO",
              "value": "Keith A. Goldan, Chief Financial Officer and Treasurer of the Company"
            },
            {
              "key": "Certification Date",
              "value": "February 28, 2023"
            },
            {
              "key": "Exhibit Reference",
              "value": "Exhibit 32.1 attached to the Annual Report"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_dividend_policy_changes": {
      "value": true,
      "elements": [
        {
          "type": "dividend_policy",
          "page": 58,
          "title": "PART II Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities",
          "data": [
            {
              "key": "Exchange Market",
              "value": "Nasdaq Global Select Market"
            },
            {
              "key": "Trading Symbol",
              "value": "SNDX"
            },
            {
              "key": "Trading Start Date",
              "value": "March 2, 2016"
            },
            {
              "key": "Holders of Record",
              "value": "Approximately 18 as of February 22, 2023"
            },
            {
              "key": "Dividend Policy",
              "value": "The company has never declared or paid any cash dividends and currently intends to retain future earnings to fund business growth. Future dividend payments will be at the discretion of the board of directors based on various factors."
            },
            {
              "key": "Performance Graph Information",
              "value": "Comparison of annual cumulative total shareholder return on common shares against the Nasdaq Composite Index and the Nasdaq Biotechnology Index from December 31, 2017 through 2022, assuming reinvestment of dividends."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_share_buyback_plans": {
      "value": true,
      "elements": [
        {
          "type": "share_buyback",
          "page": 57,
          "title": "Share Premium & Property Disclosures",
          "data": [
            {
              "key": "Common Stock Premium",
              "value": "The document mentions that stockholders may receive a premium for their shares of common stock, which could influence investor pricing."
            },
            {
              "key": "Properties",
              "value": "Headquarters located in Waltham, Massachusetts, comprising 12,207 square feet of leased office space (lease expiring on February 28, 2025) and an additional 4,039 square feet in New York, New York (lease expiring on August 31, 2025)."
            },
            {
              "key": "Legal Proceedings",
              "value": "The document states that the company is not currently a party to any material legal proceedings."
            },
            {
              "key": "Mine Safety Disclosures",
              "value": "Not applicable."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_capital_structure_changes": {
      "value": true,
      "elements": [
        {
          "type": "capital_structure",
          "page": 88,
          "title": "Stockholders' Equity Statement",
          "data": [
            {
              "key": "Row 1",
              "value": "Date: January 1, 2020; Shares: 27,140,484; Par Value: 3; Additional Paid-In Capital: 527,067; Accumulated Deficit: (495,470); Total Equity: 31,600"
            },
            {
              "key": "Row 2",
              "value": "Date: December 31, 2020; Shares: 47,881,223; Par Value: 5; Additional Paid-In Capital: 820,815; Accumulated Deficit: (568,628); Total Equity: 252,188"
            },
            {
              "key": "Row 3",
              "value": "Date: December 31, 2021; Shares: 54,983,105; Par Value: 6; Additional Paid-In Capital: 952,019; Accumulated Deficit: (543,702); Total Equity: 408,368"
            },
            {
              "key": "Row 4",
              "value": "Date: December 31, 2022; Shares: 68,111,385; Par Value: 7; Additional Paid-In Capital: 1,161,288; Accumulated Deficit: (693,040); Total Equity: 467,449"
            },
            {
              "key": "Summary",
              "value": "This table shows the Statement of Stockholders' Equity from January 2020 to December 2022. Key observations include a significant increase in shares, growth in additional paid-in capital, an increase in accumulated deficit, and overall improvement in total equity driven by capital raises and stock issuances. The accompanying notes are an integral part of these consolidated financial statements."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_structure",
          "page": 112,
          "title": "Syndax Corporate Entities and Their Locations",
          "data": [
            {
              "key": "Table Summary",
              "value": "The table displays the geographical distribution of Syndax's corporate entities across three jurisdictions. It shows Syndax's presence in the United States (Massachusetts), United Kingdom, and continental Europe (Netherlands), suggesting a multinational corporate structure."
            },
            {
              "key": "Subsidiary 1 Company",
              "value": "Syndax Securities Corporation"
            },
            {
              "key": "Subsidiary 1 Location",
              "value": "Massachusetts"
            },
            {
              "key": "Subsidiary 2 Company",
              "value": "Syndax Limited"
            },
            {
              "key": "Subsidiary 2 Location",
              "value": "United Kingdom"
            },
            {
              "key": "Subsidiary 3 Company",
              "value": "Syndax Europe B.V."
            },
            {
              "key": "Subsidiary 3 Location",
              "value": "Netherlands"
            },
            {
              "key": "Exhibit",
              "value": "Exhibit 21.1"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "mentions_new_risk_factors": {
      "value": true,
      "elements": [
        {
          "type": "risk_factor",
          "page": 15,
          "title": "Patent Uncertainty and Portfolio Overview",
          "data": [
            {
              "key": "Patent Grant Uncertainty",
              "value": "The document highlights uncertainty regarding whether owned, licensed, or pending patent applications will result in granted patents and offer sufficient protection for the technology."
            },
            {
              "key": "Dependence on Patent Protection",
              "value": "Success depends significantly on the ability to obtain, maintain, and defend patents, preserve trade secrets, and operate without infringing third-party rights."
            },
            {
              "key": "Axatilimab Patent Portfolio",
              "value": "In-licensed portfolio from UCB includes 2 granted US patents, 27 granted non-US patents (including an EP patent validated in 37 countries), and 16 pending non-US applications. Owned portfolio includes pending US and non-US applications with potential expiration dates of May 2038 or December 2040 or later, subject to patent term extensions."
            },
            {
              "key": "Menin Asset Patent Portfolio",
              "value": "In-licensed portfolio from Vitae Pharmaceuticals, Inc. features a combination of granted and pending US and non-US patents, with expected expirations around June to September 2037. Owned portfolios and co-owned applications include pending US, non-US, and PCT applications, with potential expirations ranging from April 2041 to May 2043, subject to extensions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 20,
          "title": "FDA Regulatory Approvals and Product Safety",
          "data": [
            {
              "key": "Regulatory Approval Limitations",
              "value": "FDA approvals may be limited to specific disease states, dosages, or have management plans."
            },
            {
              "key": "Phase 4 Testing",
              "value": "FDA may require post-approval testing to assess drug safety and effectiveness."
            },
            {
              "key": "Risk Evaluation and Mitigation Strategy (REMS)",
              "value": "FDA may require a REMS for the safe use of drugs."
            },
            {
              "key": "Breakthrough Therapy Designation",
              "value": "FDA can expedite reviews for drugs demonstrating significant treatment benefits."
            },
            {
              "key": "Post-Approval Regulations",
              "value": "Products are subject to ongoing FDA regulations, including cGMP compliance."
            },
            {
              "key": "Consequences of Noncompliance",
              "value": "Noncompliance can result in halted trials, approval failures, and penalties."
            },
            {
              "key": "Doctor Prescribing Freedom",
              "value": "Doctors can prescribe approved drugs broadly, while companies must adhere strictly to FDA claims."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 26,
          "title": "Risk Factors",
          "data": [
            {
              "key": "Environmental Commitment",
              "value": "We are committed to reducing our environmental footprint."
            },
            {
              "key": "Charitable Giving",
              "value": "We enable our employees to participate in various charity events."
            },
            {
              "key": "Corporate Structure",
              "value": "We were incorporated in Delaware in 2005 and have established several subsidiaries."
            },
            {
              "key": "Lease Information",
              "value": "Our principal office is located in Waltham, Massachusetts."
            },
            {
              "key": "SEC Filings",
              "value": "We file electronically with the SEC, including annual reports on Form 10-K."
            },
            {
              "key": "Forward-Looking Statements",
              "value": "This Annual Report contains forward-looking information based on our current expectations."
            },
            {
              "key": "Risk Factors",
              "value": "Numerous risks and uncertainties including the ability to complete development and commercialization of product candidates."
            },
            {
              "key": "Product Candidates",
              "value": "Our business may be affected if we are unable to develop and commercialize our product candidates."
            },
            {
              "key": "Clinical Testing",
              "value": "Revumenib and Axatilimab have undergone limited clinical testing."
            },
            {
              "key": "Interim Data Changes",
              "value": "Interim top-line and preliminary data from our clinical trials may change."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 27,
          "title": "Risks Related to Our Business and Industry",
          "data": [
            {
              "key": "Regulatory approval challenges",
              "value": "The regulatory approval processes of the FDA and foreign regulatory authorities are lengthy and unpredictable."
            },
            {
              "key": "Market acceptance risk",
              "value": "Our product candidates may not achieve adequate market acceptance among key stakeholders."
            },
            {
              "key": "Dependence on third-party suppliers",
              "value": "We rely on third-party suppliers for manufacturing and distribution of our clinical drug supplies."
            },
            {
              "key": "Financial losses",
              "value": "We have incurred net losses and may continue to do so, lacking revenue."
            },
            {
              "key": "Need for additional capital",
              "value": "We will require additional capital to finance our operations."
            },
            {
              "key": "Intellectual property risks",
              "value": "Inability to protect intellectual property may hinder our competitiveness."
            },
            {
              "key": "Stock price volatility",
              "value": "The market price of our stock may be volatile, posing investment risks."
            },
            {
              "key": "Clinical development hurdles",
              "value": "Failure to complete clinical development and obtain approvals may harm our business prospects."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 29,
          "title": "Risk Factors and Clinical Trial Update for axatilimab in cGVHD",
          "data": [
            {
              "key": "Therapeutic Area",
              "value": "cGVHD and other fibrotic/inflammatory diseases"
            },
            {
              "key": "Mechanism",
              "value": "CSF-1/CSF-1R signaling implicated in macrophage expansion and tissue infiltration"
            },
            {
              "key": "Product Candidate",
              "value": "axatilimab, a CSF-1R signal inhibitor"
            },
            {
              "key": "Clinical Trial Phases",
              "value": "Phase 1/2 trial conducted; pivotal Phase 2 trial (AGAVE-201) initiated"
            },
            {
              "key": "Patient Population",
              "value": "Subjects with active cGVHD who have failed at least two prior lines of therapy"
            },
            {
              "key": "Regulatory Path",
              "value": "Aligned with FDA following end of Phase 1 meeting"
            },
            {
              "key": "Interim Data Warning",
              "value": "Preliminary/interim data subject to change and may not predict final outcomes"
            },
            {
              "key": "Collaboration",
              "value": "Dependent on collaboration with Incyte for development and commercialization"
            },
            {
              "key": "Risk Factors",
              "value": "Delays, additional costs, and uncertainties in clinical outcomes may adversely affect business prospects"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 30,
          "title": "Potential Risks in Development and Commercialization of Axatilimab",
          "data": [
            {
              "key": "Termination of Agreement Notice",
              "value": "Incyte may terminate the agreement for convenience upon 90 or 180 days’ notice depending on commercialization."
            },
            {
              "key": "Change of Focus",
              "value": "Incyte may change the focus of its development efforts on axatilimab."
            },
            {
              "key": "Acquisition Impact",
              "value": "If Incyte is acquired, the new acquirer may have competing priorities."
            },
            {
              "key": "Risks in Clinical Trials",
              "value": "Patient enrollment challenges may delay clinical trials."
            },
            {
              "key": "Factors Affecting Enrollment",
              "value": "Public health crises, perception of efficacy, standard of care, patient population size, trial site competition."
            },
            {
              "key": "Relinquishing Control",
              "value": "Potential loss of rights to control development and commercialization with collaborators."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 31,
          "title": "Strategic Collaboration and Regulatory Risks",
          "data": [
            {
              "key": "strategic_collaboration_risks",
              "value": "Strategic collaborators may delay clinical trials, provide insufficient funding, terminate a clinical trial or abandon a product candidate, repeat or conduct new clinical trials, or require a new version for clinical testing; they may not pursue further development and commercialization of products arising from the collaboration or may discontinue R&D programs; they might not commit adequate resources to marketing and distribution, limiting potential revenues; disputes may lead to delays, termination of research, costly litigation or arbitration that diverts management’s attention; collaborators may face financial difficulties or fail to properly maintain or defend intellectual property rights, potentially jeopardizing proprietary information; business combinations or shifts in a collaborator’s strategy could adversely affect their ability to meet obligations; collaborators could advance competing product candidates or terminate/let expire the arrangement, increasing development costs and delays; and overall, strategic collaborations may never materialize or may fail."
            },
            {
              "key": "regulatory_approval_risk",
              "value": "The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable. The approval process typically requires extensive preclinical studies and clinical trials to establish safety and effectiveness, compliance with GMP, GLP, and GCP practices, and may take many years to complete. Changes in approval policies or requirements during clinical development add further uncertainty, and our inability to obtain regulatory approval could harm our business."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 35,
          "title": "Risks Associated with Undesirable Side Effects of Product Candidates",
          "data": [
            {
              "key": "Regulatory Approval Risk",
              "value": "Undesirable side effects from product candidates could interrupt, delay, or halt clinical trials and lead to delays or denials of regulatory approval by the FDA or foreign regulatory authorities."
            },
            {
              "key": "Clinical Trial Disruption",
              "value": "High severity and prevalence of side effects may result in suspended or terminated trials, affecting patient recruitment and completion rates."
            },
            {
              "key": "Market Impact",
              "value": "Adverse drug effects could lead to significant negative consequences such as product withdrawal, recall, label restrictions, or additional warnings."
            },
            {
              "key": "Post-Marketing Risks",
              "value": "If marketed, later identification of harmful side effects might trigger safety alerts, additional monitoring requirements, and potential product liability claims."
            },
            {
              "key": "International Regulatory Challenges",
              "value": "International approvals involve additional testing, varying timelines, and other regulatory challenges that could delay or prevent market entry."
            },
            {
              "key": "Financial and Business Impact",
              "value": "These risks collectively may harm the company's business, financial condition, and prospects, especially if regulatory setbacks occur."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 37,
          "title": "Risk Factors Related to Misconduct, Regulatory Compliance, and Talent Challenges",
          "data": [
            {
              "key": "Misconduct Risk",
              "value": "Employees, consultants, and collaborators may engage in misconduct including insider trading, fraudulent, illegal, or unauthorized activities that violate regulatory standards."
            },
            {
              "key": "Regulatory Compliance Risk",
              "value": "There is exposure to risks from non-compliance with FDA and non-U.S. regulatory standards, which may lead to failures in reporting complete, accurate information and violations of manufacturing and healthcare fraud laws."
            },
            {
              "key": "Legal and Financial Consequences",
              "value": "Non-compliance or misconduct could result in governmental investigations, legal actions, significant fines, sanctions, and other penalties including civil, criminal, and administrative actions."
            },
            {
              "key": "Talent Recruitment and Retention Risk",
              "value": "Challenges in recruiting, retaining, and motivating highly skilled personnel, particularly executive-level staff, could adversely affect business operations and the execution of the business plan."
            },
            {
              "key": "Pricing and Reimbursement Risk",
              "value": "The commercialization of product candidates could be hindered by unfavorable pricing regulations or third-party payor practices affecting coverage and reimbursement."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 40,
          "title": "Risks Related to Sales, Marketing, and Distribution",
          "data": [
            {
              "key": "Challenges with internal sales and marketing development",
              "value": "We may not be able to attract and build an effective marketing or sales organization."
            },
            {
              "key": "Costs justification for marketing setup",
              "value": "The cost of establishing, training, and providing oversight for a marketing or sales force may not be justifiable in light of the revenues generated by any particular product."
            },
            {
              "key": "Success of sales and marketing efforts",
              "value": "Our direct or indirect sales and marketing efforts may not be successful."
            },
            {
              "key": "Legal and regulatory risks",
              "value": "Significant legal and regulatory risks in drug marketing and sales could jeopardize our ability to market the product."
            },
            {
              "key": "Product liability exposure",
              "value": "Inherent risk of product liability exposure related to testing of our product candidates in human trials."
            },
            {
              "key": "Potential consequences of liability claims",
              "value": "Liability claims may lead to decreased demand for products, termination of trial programs, injury to reputation, significant costs in defending litigation."
            },
            {
              "key": "Insurance coverage",
              "value": "Current trial liability insurance may not cover all liabilities, and obtaining adequate coverage in the future may be challenging."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "risk_factor",
          "page": 41,
          "title": "Regulatory and Healthcare Compliance Risks",
          "data": [
            {
              "key": "Risk Factor",
              "value": "Exposure to legal and regulatory risks related to healthcare provider relationships and business arrangements."
            },
            {
              "key": "Relevant Laws",
              "value": "Anti-Kickback Statute, False Claims Act, HIPAA, HITECH, Physician Payments Sunshine Act, and analogous state/foreign laws."
            },
            {
              "key": "Potential Consequences",
              "value": "Criminal sanctions, civil penalties, contractual damages, reputational harm, fines, exclusion from government healthcare programs, operational restrictions, and diminished profits."
            },
            {
              "key": "Affected Parties",
              "value": "Healthcare providers, customers, and third-party payors involved in the recommendation, prescription, marketing, sale, and distribution of products."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 42,
          "title": "Risk Factors: Regulatory Compliance and Cybersecurity",
          "data": [
            {
              "key": "Compliance Requirements",
              "value": "Drug manufacturers are required to report payments, pricing information, and registrations, while also complying with various state, federal, and foreign healthcare laws, complicating efforts due to differing regulations."
            },
            {
              "key": "Legal and Financial Exposure",
              "value": "Non-compliance with applicable healthcare and data protection laws may result in significant civil, criminal, and administrative penalties, including fines, damages, and reputational harm."
            },
            {
              "key": "Cybersecurity Vulnerabilities",
              "value": "The dependence on information technology systems, remote work setups, and third-party vendors increases the risk of cyberattacks, which could lead to data breaches and further legal and financial repercussions."
            },
            {
              "key": "Operational Impact",
              "value": "Ensuring adherence to complex regulations may incur substantial costs and require significant resource allocation, potentially disrupting business operations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 43,
          "title": "Risks Related to Data Security and Business Operations",
          "data": [
            {
              "key": "Data Security Risks",
              "value": "Significant disruptions of our, our third-party vendors’ and/or business partners’ information technology systems could adversely affect our business operations, resulting in loss or unauthorized access to sensitive information."
            },
            {
              "key": "Causes of Disruption",
              "value": "Disruptions can occur due to attacks, computer viruses, natural disasters, terrorism, war, and telecommunication failures."
            },
            {
              "key": "Impact on Clinical Trials",
              "value": "Loss of clinical trial data could delay regulatory approval efforts and significantly increase recovery costs."
            },
            {
              "key": "Potential Unknown Incidents",
              "value": "There is a risk of undetected data security incidents."
            },
            {
              "key": "Consequences of Breaches",
              "value": "Unauthorized access could lead to legal and reputational harm, compliance issues with privacy laws, and significant costs."
            },
            {
              "key": "Compliance Risks",
              "value": "Failure to comply with privacy or data security laws could lead to governmental investigations, enforcement actions, and loss of trust."
            },
            {
              "key": "Control Mechanisms",
              "value": "While security measures are implemented, there's no assurance they will prevent security incidents."
            },
            {
              "key": "Impact of Work-from-Home Policies",
              "value": "COVID-19 policies may have led to less secure handling of confidential information."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 45,
          "title": "Risk Factor: Funding and Economic Uncertainty",
          "data": [
            {
              "key": "Additional Capital Requirement",
              "value": "The company requires additional capital to continue development, obtain regulatory approval, and commercialize existing and future product candidates."
            },
            {
              "key": "Management Distraction",
              "value": "Efforts to secure additional financing may divert management from day-to-day activities, potentially impacting product development and commercialization."
            },
            {
              "key": "Global Economic Disruptions",
              "value": "Events such as the COVID-19 pandemic and the war between Russia and Ukraine have disrupted global financial markets and contributed to an economic slowdown."
            },
            {
              "key": "Inflation and Rising Costs",
              "value": "Increased inflation rates are driving up operating costs including labor."
            },
            {
              "key": "Interest Rate Hikes",
              "value": "The U.S. Federal Reserve has raised and is expected to further raise interest rates in response to inflation concerns, amplifying economic uncertainty."
            },
            {
              "key": "Risk of Inadequate Funding",
              "value": "If additional capital cannot be raised on favorable terms, the company may need to delay, scale back, or discontinue development and commercialization efforts, or may have to license or relinquish rights to technologies."
            },
            {
              "key": "Factors Influencing Future Funding",
              "value": "Future funding requirements depend on clinical trial progress, regulatory approvals, intellectual property costs, market acceptance, manufacturing and sales infrastructure, competitive developments, and internal system enhancements."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 47,
          "title": "Patent Prosecution Risks and Intellectual Property Challenges",
          "data": [
            {
              "key": "Cost and Timeliness",
              "value": "The patent prosecution process is expensive and time-consuming, which may hinder the timely filing and prosecution of patent applications."
            },
            {
              "key": "Control and Cooperation Risks",
              "value": "Dependence on licensors and licensees to manage patent filings and enforcement may compromise patent protection if there is a lack of cooperation or disagreement."
            },
            {
              "key": "Patent Protection Uncertainty",
              "value": "There is significant uncertainty regarding the issuance, scope, validity, and enforceability of patents, which may affect the company’s ability to protect its technology."
            },
            {
              "key": "Competitor and Prior Art Challenges",
              "value": "Competitors may achieve patents that block commercial efforts and prior art issues could potentially affect the validity or enforceability of patent claims."
            },
            {
              "key": "Patent Expiration Concerns",
              "value": "Licensed patents, such as those related to entinostat, have expired or may expire before the commercialization of related products, limiting effective market protection."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 50,
          "title": "License Agreement Obligations and Associated Risks",
          "data": [
            {
              "key": "AbbVie License Terms",
              "value": "Obligation to pay low single- to low double-digit royalties on revumenib sales, milestone payments up to $70 million, and possible sharing of non-royalty income from sublicensees."
            },
            {
              "key": "Bayer License Terms",
              "value": "Worldwide exclusive license for entinostat; milestone payments (~$50 million for development and $100 million in sales milestones) and tiered, single-digit royalties on net sales."
            },
            {
              "key": "Termination Provisions",
              "value": "Either party may terminate upon uncured material breach, bankruptcy, assignment for creditors, or specific insolvency events. Licensors may also terminate if patent validity challenges occur."
            },
            {
              "key": "Duration of Royalty Obligations",
              "value": "Payments continue until expiration of licensed patent rights, regulatory exclusivity, or 10/15 years from first commercial sale, whichever is longer; dates uncertain due to no commercial sales to date."
            },
            {
              "key": "Risk Implications",
              "value": "Termination of agreements would eliminate the ability to develop, manufacture, market or sell the licensed products, posing a significant business risk."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "risk_factor",
          "page": 51,
          "title": "Patent Law Changes and Intellectual Property Risk",
          "data": [
            {
              "key": "Risk Factor",
              "value": "Changes in patent law could diminish the value of patents and impair the ability to protect product candidates."
            },
            {
              "key": "Legislation",
              "value": "The America Invents Act, signed on September 16, 2011 and effective from March 16, 2013, introduces significant changes that may affect patent prosecution and litigation."
            },
            {
              "key": "Enforcement Challenges",
              "value": "Obtaining and enforcing biopharmaceutical patents is costly, time-consuming, and fraught with legal and procedural uncertainties."
            },
            {
              "key": "Compliance and Maintenance",
              "value": "Failure to comply with procedural requirements, fee payments, and document submissions could result in abandonment or lapse of patent rights."
            },
            {
              "key": "Business Impact",
              "value": "Increased uncertainties and potential litigation risks may harm the company's business operations and financial condition."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 52,
          "title": "Litigation and Intellectual Property Risk",
          "data": [
            {
              "key": "Risk Description",
              "value": "The text outlines potential litigation risks related to intellectual property, including difficulties in preventing infringement, risks of patent invalidation, and possible costly legal proceedings."
            },
            {
              "key": "Impact",
              "value": "Litigation could lead to substantial financial costs, diversion of management resources, harm to business operations, and downward pressure on stock price."
            },
            {
              "key": "Legal Proceedings",
              "value": "Mentions various legal challenges such as infringement lawsuits, patent validity disputes, pre-issuance submissions, oppositions, reexaminations, inter partes reviews, and interference proceedings."
            },
            {
              "key": "Consequences",
              "value": "Adverse litigation outcomes may force cessation of technology use or product commercialization, and may result in monetary damages including treble damages and attorney fees."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 53,
          "title": "Risk Factors Related to Intellectual Property and Competitive Position",
          "data": [
            {
              "key": "Employee Background Risks",
              "value": "Many employees, including senior management, come from universities and biotechnology/pharmaceutical companies (including competitors), which may expose the company to risks relating to proprietary information."
            },
            {
              "key": "Confidentiality and IP Agreements",
              "value": "Employees have executed proprietary rights, non-disclosure, and non-competition agreements, but there remains a risk of using or disclosing confidential or proprietary information from previous employers."
            },
            {
              "key": "Litigation Risk",
              "value": "The company may face litigation claims alleging the misuse or disclosure of confidential information or trade secrets, which could result in costly legal battles and potential loss of intellectual property rights."
            },
            {
              "key": "Patent and Invention Assignment Risks",
              "value": "For some in-licensed patents and patent applications, incomplete access to patent assignments or employee agreements may lead to ownership disputes over inventions."
            },
            {
              "key": "Trade Secrets and Competitive Risks",
              "value": "Reliance on trade secrets and unpatented know-how creates challenges in enforcement; breaches of confidentiality agreements could undermine the company’s competitive position."
            },
            {
              "key": "Market Volatility",
              "value": "The text also mentions risks related to the volatile market price of the company’s stock driven by competitive developments, litigation, and other risk factors."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 54,
          "title": "Risk Factors: Market, Financial, and Operational Risks",
          "data": [
            {
              "key": "Product Development Expenses",
              "value": "the level of expenses related to our product candidates or clinical development programs"
            },
            {
              "key": "Financial Estimate Changes",
              "value": "actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts"
            },
            {
              "key": "Financial Results Variations",
              "value": "variations in our financial results or those of companies that are perceived to be similar to us"
            },
            {
              "key": "Valuation Fluctuations",
              "value": "fluctuations in the valuation of companies perceived by investors to be comparable to us"
            },
            {
              "key": "Share Price and Volume Volatility",
              "value": "share price and volume fluctuations attributable to inconsistent trading volume levels of our shares"
            },
            {
              "key": "Financing Announcements",
              "value": "announcement or expectation of additional financing efforts"
            },
            {
              "key": "Equity Sales",
              "value": "sales of our common stock by us, our insiders or our other stockholders"
            },
            {
              "key": "Healthcare Payment System Changes",
              "value": "changes in the structure of healthcare payment systems"
            },
            {
              "key": "Industry and Market Conditions",
              "value": "market conditions in the pharmaceutical and biotechnology sectors; general economic, industry, political and market conditions, including new or ongoing public health crises and geopolitical conflicts such as the war between Russia and Ukraine"
            },
            {
              "key": "Market Volatility Impact",
              "value": "extreme price and volume fluctuations in the stock market unrelated or disproportionate to operating performance, affecting the market price of our common stock"
            },
            {
              "key": "Economic and Financing Risks",
              "value": "risk factors including unstable market and economic conditions, disruptions in credit and liquidity, and potential dilution from additional equity or debt financing"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "risk_factor",
          "page": 55,
          "title": "Risk Factors and Financial Disclosures",
          "data": [
            {
              "key": "Additional Funding Risk",
              "value": "The company may seek government or third-party funding, but such additional funding may not be available on reasonable terms."
            },
            {
              "key": "Securities Rights and Covenants",
              "value": "Securities issued may have rights senior to common stock and include covenants that restrict the company’s operations, such as limitations on incurring further debt or acquiring/licensing intellectual property."
            },
            {
              "key": "Analyst Coverage Impact",
              "value": "Lack of analyst coverage or adverse opinions from analysts could lead to a decline in stock price and trading volume."
            },
            {
              "key": "Controlling Stockholder Influence",
              "value": "Significant ownership by principal stockholders and management may lead to decisions that favor their interests and potentially deter unsolicited acquisition proposals."
            },
            {
              "key": "Securities Litigation Risk",
              "value": "The company faces risks of expensive securities litigation, which could divert management attention and harm the business."
            },
            {
              "key": "Internal Control over Financial Reporting",
              "value": "Failure to maintain an effective system of internal control over financial reporting could result in inaccurate financial disclosures and negatively impact investor confidence."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 56,
          "title": "Risk Factors: Internal Control over Financial Reporting",
          "data": [
            {
              "key": "Internal Control Attestation Requirement",
              "value": "The company must obtain an attestation from an independent registered public accounting firm on the effectiveness of internal control over financial reporting."
            },
            {
              "key": "Section 404 Compliance",
              "value": "Compliance with Section 404 requires substantial expense, significant management efforts, and may necessitate hiring additional accounting and financial staff."
            },
            {
              "key": "Lack of Internal Audit Group",
              "value": "The company currently does not have an internal audit group, increasing the risk of incomplete evaluation and testing."
            },
            {
              "key": "Risk of Material Weaknesses",
              "value": "There is a risk that material weaknesses or significant deficiencies in internal controls may be identified, preventing an assertion of effective controls."
            },
            {
              "key": "Impact on Financial Reporting",
              "value": "Failure to maintain effective internal controls could inhibit the company's ability to accurately report financial condition, results of operations, or cash flows."
            },
            {
              "key": "Investor and Regulatory Risks",
              "value": "Material weaknesses could lead to loss of investor confidence, stock price decline, and potential sanctions or investigations by regulatory authorities (e.g., Nasdaq, SEC)."
            },
            {
              "key": "Anti-Takeover Provisions",
              "value": "Charter documents and Delaware law include provisions such as a classified board and restrictions on change of control, which may deter or delay acquisitions or management changes."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 62,
          "title": "Risk Factors and Financial Overview",
          "data": [
            {
              "key": "Risk Overview",
              "value": "The document details risks arising from the ongoing war between Russia and Ukraine, worsening global macroeconomic conditions, employee availability issues, and wage increases, potentially stressing working capital resources."
            },
            {
              "key": "Business and Industry Challenges",
              "value": "It highlights challenges specific to the company’s business such as executing its strategy, obtaining regulatory approval for late-stage product candidates, acquiring or in-licensing additional products, and navigating uncertainties in pharmaceutical product development, including clinical and intellectual property risks."
            },
            {
              "key": "Financial Overview",
              "value": "The report notes that no product revenues have been generated to date. Instead, revenue has been derived from license, development, and commercialization agreements with partners like Kyowa Kirin Co., Ltd. (KKC) and Incyte Pharmaceuticals, Inc. Details include upfront cash payments, share purchase agreements, and revenue adjustments due to program discontinuations."
            },
            {
              "key": "Collaboration Details",
              "value": "The collaboration with Incyte involves exclusive commercialization rights outside of the United States, joint development cost sharing (55% by Incyte and 45% by the company), and co-commercialization rights in the U.S., whereas the KKC agreement involved licensing for Japan and Korea, with subsequent cancellation of the entinostat program affecting revenue recognition."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "risk_factor",
          "page": 71,
          "title": "Net Operating Loss & Research and Development Tax Credit Carryforwards and Market Risk Disclosures",
          "data": [
            {
              "key": "Federal NOL Carryforwards",
              "value": "Approximately $99.6 million"
            },
            {
              "key": "State NOL Carryforwards",
              "value": "Approximately $42.8 million"
            },
            {
              "key": "Indefinite Federal NOLs",
              "value": "$77.5 million with an indefinite carryforward period"
            },
            {
              "key": "Expiring Federal NOLs",
              "value": "$22.1 million beginning to expire starting in 2026"
            },
            {
              "key": "Total Available Income Tax Credits",
              "value": "Approximately $8.9 million"
            },
            {
              "key": "Federal R&D Credits",
              "value": "$5.7 million"
            },
            {
              "key": "State R&D Credits",
              "value": "$3.2 million (begin expired in 2022)"
            },
            {
              "key": "Deferred Tax Assets Valuation Allowance",
              "value": "Recorded on all deferred tax assets including NOLs and R&D tax credit carryforwards"
            },
            {
              "key": "Cash, Cash Equivalents, and Investments",
              "value": "$481.3 million, comprising overnight investments, money market funds, federal bonds, commercial paper, corporate bonds and treasuries"
            },
            {
              "key": "Market Risk Exposure",
              "value": "Primarily interest rate sensitivity due to changes in U.S. interest rates with minimal impact from a 100 basis point change"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "risk_factor",
          "page": 91,
          "title": "SYNDAX PHARMACEUTICALS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS",
          "data": [
            {
              "key": "Business Description",
              "value": "Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies, with two lead product candidates: revumenib (SNDX-5613) and axatilimab (SNDX-6352)."
            },
            {
              "key": "Product Focus",
              "value": "Revumenib targets the menin-MLL1 interaction for acute leukemias (KMT2Ar and NPM1 mutant AML), while axatilimab targets the CSF-1 receptor for conditions like chronic graft-versus-host disease and idiopathic pulmonary fibrosis."
            },
            {
              "key": "Operational Focus",
              "value": "The Company has devoted efforts to research and development and raising capital, and anticipates continued investment in R&D despite ongoing losses and future funding requirements."
            },
            {
              "key": "Risk Factors",
              "value": "Risks include challenges in successful therapeutic development, obtaining regulatory approvals, supply chain issues, dependence on critical personnel and collaborators, and the need for additional capital to support ongoing clinical trials and operations."
            },
            {
              "key": "Financial Statement Basis",
              "value": "The consolidated financial statements are prepared in accordance with U.S. GAAP."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_guidance_updates": {
      "value": true,
      "elements": [
        {
          "type": "guidance_update",
          "page": 3,
          "title": "Forward-Looking Statements",
          "data": [
            {
              "key": "description",
              "value": "This section includes forward-looking statements concerning potential future outcomes, expectations regarding expenses, revenues, capital requirements, research and development activities, regulatory approvals, and business strategies."
            },
            {
              "key": "factors",
              "value": "Mentioned factors affecting forward-looking statements include market conditions, competition, regulatory environments, collaborations, and global events."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 4,
          "title": "Estimates and Projections in Annual Report",
          "data": [
            {
              "key": "Estimated Market Size",
              "value": "Data regarding the estimated size of certain markets"
            },
            {
              "key": "Projected Growth Rates",
              "value": "Projected growth rates for certain drugs and consumer products"
            },
            {
              "key": "Medical Conditions Incidence",
              "value": "Incidence of certain medical conditions"
            },
            {
              "key": "Data Sources",
              "value": "Reports, research surveys, studies, government data from third parties"
            },
            {
              "key": "Company References",
              "value": "References to Syndax and its subsidiaries"
            },
            {
              "key": "Trademark References",
              "value": "Usage of trademarks and trade names for convenience without registration symbols"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 21,
          "title": "Regulatory Challenges and Market Acceptance of Medical Products",
          "data": [
            {
              "key": "Concerns about Advertising",
              "value": "Claims in advertising must balance safety information; non-compliance can lead to penalties."
            },
            {
              "key": "Government Scrutiny",
              "value": "Increased scrutiny of drug promotion and marketing."
            },
            {
              "key": "Coverage and Reimbursement Challenges",
              "value": "Sales depend on coverage and reimbursement from third-party payors."
            },
            {
              "key": "Impact of Third-Party Payors",
              "value": "Coverage decisions may vary based on clinical and economic standards."
            },
            {
              "key": "Marketability Issues",
              "value": "Marketability may suffer if adequate reimbursement is not provided."
            },
            {
              "key": "Regulatory Pressure on Pricing",
              "value": "Government may limit or regulate prices of medical products."
            },
            {
              "key": "Formulary Inclusion Competition",
              "value": "Competition for inclusion on payors’ formularies affects pricing."
            },
            {
              "key": "Approval Process",
              "value": "Obtaining coverage requires time, effort, and may not guarantee success."
            },
            {
              "key": "Cost-Effectiveness Concerns",
              "value": "Demonstrating cost-effectiveness is key for reimbursement."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 23,
          "title": "Regulatory and Compliance Overview",
          "data": [
            {
              "key": "Legal Risks",
              "value": "We may be subject to federal and state laws governing privacy and security of personal information, leading to potential legal actions."
            },
            {
              "key": "Data Breach Implications",
              "value": "Data breaches could lead to significant financial exposure and reputational damage."
            },
            {
              "key": "Potential Penalties",
              "value": "Violating laws could result in civil and criminal penalties including fines and imprisonment."
            },
            {
              "key": "Impact of Healthcare Reform",
              "value": "Legislative changes like the Affordable Care Act significantly affect the pharmaceutical industry."
            },
            {
              "key": "Key Provisions of the Affordable Care Act",
              "value": "Includes fee for manufacturers, increase in Medicaid rebates, and expanded fraud laws."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 46,
          "title": "Risk Factors Related to Business Interruption and Tax Law Changes",
          "data": [
            {
              "key": "business_interruption",
              "value": "business interruptions resulting from geo-political actions, including war, terrorism, natural disasters, or public health crises."
            },
            {
              "key": "tax_law_changes",
              "value": "Changes in tax laws or regulations could materially adversely affect the company, especially with regard to the Tax Cuts and Jobs Act."
            },
            {
              "key": "ownership_change_implications",
              "value": "An ownership change may limit the use of net operating loss carryforwards, impacting future tax capacity."
            },
            {
              "key": "intellectual_property_risks",
              "value": "Inability to protect intellectual property may hinder competitive advantage."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 68,
          "title": "Future Capital Requirements and Factors Influencing Estimates",
          "data": [
            {
              "key": "Key Considerations",
              "value": "The future capital requirements will depend on various factors including clinical trial activities, regulatory approvals, intellectual property costs, market acceptance, and manufacturing capabilities."
            },
            {
              "key": "Current Financial Situation",
              "value": "No products approved for commercial sale and no product revenues generated to date."
            },
            {
              "key": "Funding Sources",
              "value": "Expect financing through equity offerings, debt financings, and additional funding from collaborations."
            },
            {
              "key": "Contractual Obligations",
              "value": "Material cash requirements include various contractual obligations with impacts on liquidity."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 74,
          "title": "Disclosure About Changes in Compliance Conditions",
          "data": [
            {
              "key": "Changes in Compliance",
              "value": "Inadequate because of changes in conditions"
            },
            {
              "key": "Disclosure Date",
              "value": "February 28, 2023"
            },
            {
              "key": "Other Information",
              "value": "None"
            },
            {
              "key": "Foreign Jurisdictions",
              "value": "Not Applicable"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 76,
          "title": "Financial Statements Summary",
          "data": [
            {
              "key": "Summary",
              "value": "This table appears to be a table of contents for a financial report, listing various financial statements and their corresponding page numbers. It includes key financial documents such as the auditor's report (on page F-2), balance sheets (on page F-4), and various other consolidated financial statements covering the years 2020-2022. Most of the statements don't have page numbers listed, suggesting this might be a preliminary version or the page numbers were omitted in the extraction."
            },
            {
              "key": "Exhibits Summary",
              "value": "This table presents a list of exhibits from various SEC filings of the company. It includes corporate governance documents (exhibits 3.1-3.2), securities-related documents (exhibits 4.1-4.3), and multiple amendments to the 2007 Stock Plan (exhibits 10.1-10.4). The exhibits span from 2013 to 2021, with most documents being incorporated from the company's S-1 Registration Statement and Form 8-K filings. The asterisk (*) next to exhibit numbers 10.1-10.4 likely indicates these are management contracts or compensatory plans."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 97,
          "title": "Incyte Agreement and License Revenue Recognition",
          "data": [
            {
              "key": "Transaction Price Allocated",
              "value": "$126.6 million"
            },
            {
              "key": "Performance Obligation",
              "value": "License for SNDX-6532"
            },
            {
              "key": "Revenue Recognition Date",
              "value": "Year ended December 31, 2021"
            },
            {
              "key": "Lease Accounting Standard Applied",
              "value": "ASC 842"
            },
            {
              "key": "Variable Consideration Estimate",
              "value": "Zero for preclinical, development, and regulatory milestone payments."
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_regulatory_or_litigation_issues": {
      "value": true,
      "elements": [
        {
          "type": "regulatory_litigation",
          "page": 13,
          "title": "Лицензионные соглашения и условия прекращения",
          "data": [
            {
              "key": "Termination Clauses",
              "value": "Каждая сторона может прекратить действие лицензии в случае существенного нарушения условий другой стороной или её несостоятельности. Кроме того, партнер может расторгнуть лицензионное соглашение, если его или его аффилированные лица инициируют юридический спор по вопросу действительности, принудительности или патентоспособности лицензированных прав."
            },
            {
              "key": "Bayer License Agreement",
              "value": "Соглашение с Bayer Pharma AG предоставляет всемирную эксклюзивную лицензию на разработку и коммерциализацию энтинастата. Соглашение предусматривает передачу прав производства с мая 2012 года, выплаты в виде этапных платежей (до ~$50 млн) за определённые этапы разработки и маркетингового утверждения, а также до $100 млн по объёмным этапам продаж и роялти, выплачиваемые до истечения срока действия патентных прав или в течение 15 лет после первой коммерческой продажи."
            },
            {
              "key": "Eddingpharm Agreement",
              "value": "Соглашение с Eddingpharm International Company Limited предоставляет эксклюзивную лицензию на разработку и коммерциализацию энтинастата в Китае и некоторых азиатских странах, включая права по сублицензированию. Также предусмотрены выплаты по этапам разработки и регуляторным достижениям (до $10 млн), а роялти выплачиваются до истечения действия патентов или 15 лет с момента первой коммерческой продажи в соответствующей стране."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "regulatory_litigation",
          "page": 17,
          "title": "Patent Term, Confidentiality Agreements and FDA Regulation",
          "data": [
            {
              "key": "Patent Term Details",
              "value": "The term of individual patents depends on the legal term in each country. Typically, it is 20 years from the filing date of the earliest non-provisional or PCT application. In the US, adjustments may extend or shorten the term."
            },
            {
              "key": "Patent Term Adjustment and Extension",
              "value": "US patents may be lengthened via patent term adjustment to compensate for USPTO delays, or extended under the Drug Price Competition and Patent Term Restoration Act of 1984 for new chemical entities, subject to specific criteria including regulatory review and first permitted commercialization."
            },
            {
              "key": "Confidential Information and Inventions Assignment",
              "value": "Employees and consultants must sign confidentiality agreements ensuring that inventions developed during the relationship become the company's exclusive property."
            },
            {
              "key": "Government Regulation and Product Approval",
              "value": "In the US, the FDA regulates drugs and biologics under various acts and regulations, requiring compliance with standards for testing, quality control, clinical trials, and premarket and postmarket procedures."
            },
            {
              "key": "Biopharmaceutical Product Development Process",
              "value": "The process involves extensive preclinical tests, IND application, and well-controlled clinical trials to establish safety and efficacy prior to marketing."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 22,
          "title": "Federal and State Fraud, Abuse, and Data Privacy Regulations",
          "data": [
            {
              "key": "FDA Restrictions",
              "value": "Limits marketing practices for pharmaceutical products"
            },
            {
              "key": "Anti-Kickback Statute",
              "value": "Prohibits solicitation or payment of remuneration (kickbacks, bribes, rebates) in return for healthcare-related transactions under federal programs"
            },
            {
              "key": "False Claims Act",
              "value": "Penalizes presenting false or fraudulent claims for payment from government healthcare payors"
            },
            {
              "key": "HIPAA & HITECH",
              "value": "Establishes requirements for privacy, security, and authorized transmission of individually identifiable health information"
            },
            {
              "key": "Physician Payments Sunshine Act",
              "value": "Mandates annual reporting of transfers of value to physicians and certain healthcare professionals, as well as ownership interests"
            },
            {
              "key": "State Law Requirements",
              "value": "Include additional regulations on reporting, compliance programs, pricing information, registration of sales representatives, and privacy/security of health data, complicating compliance efforts"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 24,
          "title": "Regulatory and Legislative Changes Affecting Healthcare",
          "data": [
            {
              "key": "Drug Sample Reporting Requirement",
              "value": "New requirement to annually report drug samples that manufacturers and distributors provide to physicians."
            },
            {
              "key": "Patient-Centered Outcomes Research Institute",
              "value": "Establishment of a new institute to oversee, set research priorities, and conduct comparative clinical effectiveness research along with funding."
            },
            {
              "key": "Affordable Care Act Challenges",
              "value": "Subject to executive, judicial and Congressional challenges; includes repeal of the individual mandate via the Tax Cuts and Jobs Act of 2017 and subsequent legal and procedural developments."
            },
            {
              "key": "Supreme Court Ruling",
              "value": "On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds concerning the constitutionality of the Affordable Care Act."
            },
            {
              "key": "Inflation Reduction Act (IRA)",
              "value": "Signed on August 16, 2022, extends enhanced subsidies for health insurance coverage, eliminates the Medicare Part D donut hole starting in 2025 with reduced out-of-pocket costs and a new manufacturer discount program."
            },
            {
              "key": "Drug Pricing Reforms",
              "value": "Includes executive orders and legislative inquiries aimed at increasing transparency in drug pricing, potential negotiations for high-expenditure drugs, and imposing rebates under Medicare Parts B and D."
            },
            {
              "key": "State-level Pharmaceutical Regulations",
              "value": "Legislatures are passing measures concerning price disclosure, patient reimbursement constraints, discounts, marketing cost transparency, and importation/bulk purchasing."
            },
            {
              "key": "Foreign Regulatory Requirements",
              "value": "Products sold outside the United States must obtain approval from foreign regulatory authorities before commencing clinical trials or marketing."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 28,
          "title": "Regulatory Approval Challenges and Clinical Trial Considerations",
          "data": [
            {
              "key": "FDA Requirements",
              "value": "Additional clinical trials may be required by the FDA or foreign regulatory authorities prior to marketing approval."
            },
            {
              "key": "Adverse Drug Reactions",
              "value": "Prevalence and severity of adverse drug reactions in clinical trials."
            },
            {
              "key": "Safety and Efficacy",
              "value": "Ability to demonstrate safety and efficacy of product candidates for proposed indications."
            },
            {
              "key": "Compliance",
              "value": "Achieving and maintaining compliance with all applicable regulatory requirements."
            },
            {
              "key": "Treatment Potential",
              "value": "Potential use of product candidates to treat cancer and fibrotic diseases."
            },
            {
              "key": "Market Competition",
              "value": "Availability, perceived advantages, relative cost, safety, and efficacy of competing treatments."
            },
            {
              "key": "Marketing Strategy",
              "value": "Effectiveness of marketing, sales, and distribution strategies."
            },
            {
              "key": "Manufacturing Compliance",
              "value": "Ability of collaboration partners and third-party manufacturers to comply with cGMP."
            },
            {
              "key": "Commercialization",
              "value": "Ability to successfully commercialize product candidates."
            },
            {
              "key": "Intellectual Property",
              "value": "Ability to enforce intellectual property rights."
            },
            {
              "key": "Regulatory Approval Impact",
              "value": "Failure to obtain regulatory approval for product candidates could materially adversely affect business."
            },
            {
              "key": "Clinical Testing of Revumenib",
              "value": "Limited clinical testing and the challenge to demonstrate tolerance and clinical benefit of Revumenib."
            },
            {
              "key": "Research on Acute Leukemias",
              "value": "Research indicates certain leukemias are driven by interactions involving menin and the MLL1 protein."
            },
            {
              "key": "MLLr Fusion Protein",
              "value": "Spontaneous fusion event between MLL1 and signaling molecules impacts transcription programs."
            },
            {
              "key": "Phase 1/2 Trial Strategy",
              "value": "Plan to conduct Phase 1/2 clinical trial in patients with specific acute leukemias."
            },
            {
              "key": "Trial Assessments",
              "value": "Phase 1 assessing safety, tolerability, and pharmacokinetics; Phase 2 evaluating efficacy."
            },
            {
              "key": "Risk-Benefit Evaluation",
              "value": "Need to demonstrate a favorable risk-benefit profile for continued development of Revumenib."
            },
            {
              "key": "Clinical Testing of Axatilimab",
              "value": "Limited clinical testing and the challenge to demonstrate tolerance and clinical benefit of Axatilimab."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 32,
          "title": "Regulatory Approval Risks and Market Acceptance of Product Candidates",
          "data": [
            {
              "key": "Regulatory Approval Risks",
              "value": "Product candidates may fail to receive regulatory approval due to ineffective demonstration for proposed indications, safety profile issues, and various disagreements regarding data interpretation."
            },
            {
              "key": "Clinical Trials",
              "value": "Failures in clinical trials to meet primary endpoints or statistical significance required for approval."
            },
            {
              "key": "Approval Process Delays",
              "value": "Regulatory authorities may require additional data which could delay approval and commercialization plans."
            },
            {
              "key": "Market Acceptance",
              "value": "Approval does not guarantee market acceptance among physicians and patients; success depends on a variety of factors including efficacy, safety, cost, and reimbursement."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 38,
          "title": "Challenges and Impacts of Reimbursement and Healthcare Regulations",
          "data": [
            {
              "key": "coverage_reimbursement_issues",
              "value": "Uncertainty in coverage and reimbursement for commercialized products, affecting demand and pricing."
            },
            {
              "key": "impact_of_legislation",
              "value": "Potential changes in regulations can complicate and increase the costs of marketing approval."
            },
            {
              "key": "affordable_care_act_effects",
              "value": "Introduced fees and rebates affecting drug pricing and market entry."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 39,
          "title": "Legislative and Regulatory Changes Affecting Healthcare and Drug Pricing",
          "data": [
            {
              "key": "Affordable Care Act Revisions",
              "value": "Repeal of individual mandate effective January 1, 2019, and legal precedents regarding its constitutionality."
            },
            {
              "key": "Inflation Reduction Act of 2022",
              "value": "Extends subsidies for health insurance and reduces out-of-pocket costs under Medicare."
            },
            {
              "key": "Medicare Payment Reductions",
              "value": "Aggregate reductions to Medicare payments of 2% per fiscal year, with projected variations through 2023."
            },
            {
              "key": "Drug Pricing Transparency Measures",
              "value": "Recent executive orders and legislative inquiries aimed at reformation of drug pricing practices."
            },
            {
              "key": "Biden Administration Drug Pricing Initiatives",
              "value": "Negotiations for drug pricing and penalties for non-compliance as outlined in the IRA."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 48,
          "title": "Intellectual Property Protection and Risks",
          "data": [
            {
              "key": "Patent RE45,499 details",
              "value": "The claims of the '166 patent have been surrendered in favor of RE45,499, which has the same term expiring in August 2029."
            },
            {
              "key": "Competitor risk",
              "value": "After the expiry of RE39,754, competitors may develop competing forms that could interfere with our polymorph B."
            },
            {
              "key": "Validity concerns",
              "value": "There is uncertainty regarding the ability to defend the validity of RE45,499 or its counterparts against legal challenges."
            },
            {
              "key": "NDA submission timelines",
              "value": "Even with NDA submission before RE45,499 expiration, potential extensions may only add a maximum of five years."
            },
            {
              "key": "Licensed patents from UCB",
              "value": "The portfolio includes patents related to axatilimab, with uncertain outcomes on pending applications."
            },
            {
              "key": "Expected expiration for UCB patents",
              "value": "Additional patents based on current applications may expire in 2036."
            },
            {
              "key": "Licensed patents from AbbVie",
              "value": "Includes patents on inhibitors interacting with MLL, with uncertain outcomes on pending applications."
            },
            {
              "key": "Expected expiration for AbbVie patents",
              "value": "Patents from AbbVie may expire in 2037."
            },
            {
              "key": "Intellectual property enforcement",
              "value": "Protection of intellectual property rights globally is limited and can be prohibitively expensive."
            },
            {
              "key": "Foreign enforcement challenges",
              "value": "Different intellectual property laws in foreign countries pose challenges in enforcing rights."
            },
            {
              "key": "Competitor risks due to enforcement issues",
              "value": "Competitors may exploit technologies in jurisdictions without patent protection."
            },
            {
              "key": "Ineffectiveness of patents in certain jurisdictions",
              "value": "Enforcement of patents, especially in developing countries, can be weak, affecting our ability to stop infringement."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 49,
          "title": "Patent Validity and License Agreements",
          "data": [
            {
              "key": "Patent Validity Issues",
              "value": "Our and our licensors’ patent applications at risk of being invalidated."
            },
            {
              "key": "Litigation Risks",
              "value": "Generic drug manufacturers may challenge the scope, validity or enforceability of our patents."
            },
            {
              "key": "License Agreement Risks",
              "value": "Loss of ability to develop and commercialize axatilimab if UCB license agreement is terminated."
            },
            {
              "key": "Milestone Payments",
              "value": "Potentially required to pay UCB up to $119.5 million in one-time payments."
            },
            {
              "key": "Royalty Obligations",
              "value": "Obligation to pay UCB low double-digit royalties on sales of axatilimab."
            },
            {
              "key": "Termination Conditions",
              "value": "Conditions under which either party may terminate the UCB license agreement."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_strategic_restructuring": {
      "value": false,
      "elements": []
    },
    "has_supply_chain_disruptions": {
      "value": false,
      "elements": []
    },
    "has_esg_initiatives": {
      "value": true,
      "elements": [
        {
          "type": "esg_initiative",
          "page": 25,
          "title": "Human Capital, Compensation & ESG Disclosures",
          "data": [
            {
              "key": "Regulatory Approval and Compliance",
              "value": "The document discusses variable timelines for FDA approval and highlights differing regulatory requirements for clinical trials, product licensing, manufacturing, marketing, and distribution both in the United States and abroad, including post-approval regulations."
            },
            {
              "key": "Employee Count and Composition",
              "value": "As of February 22, 2023, there were 107 full-time employees, with 68 primarily engaged in research and development and 24 holding advanced degrees (M.D. or Ph.D)."
            },
            {
              "key": "Compensation and Incentives",
              "value": "Employees receive competitive salaries, bonuses, and opportunities through equity incentive plans designed to attract, retain, and motivate staff, consultants, and directors."
            },
            {
              "key": "Human Capital Management Initiatives",
              "value": "The company emphasizes employee engagement, training, development, and benefits, including health care, retirement planning, and paid time off."
            },
            {
              "key": "Diversity, Equity and Inclusion (DEI)",
              "value": "There is a strong commitment to fostering a diverse and inclusive work environment with equal opportunities based on qualifications, performance, skills, and experience, regardless of gender, race, or ethnicity."
            },
            {
              "key": "ESG Commitment",
              "value": "The report outlines a robust commitment to Environmental, Social, and Governance practices, including support for scientific, medical, patient, and local communities, aiming for positive social impact and good corporate governance."
            }
          ],
          "currency": "N/A"
        }
      ]
    }
  },
  "currency": {
    "USD": 24,
    "EUR": 9,
    "AUD": 27,
    "CAD": 3,
    "ZAR": 3
  },
  "sha1": "e2923f240db86d0096f462f6cb398339d3251b50"
}